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Zusammenfassung 
Die septische Granulomatose (chronic granulomatous disease: CGD) umfasst eine Gruppe 
von angeborenen Immundefekten, die durch einen Ausfall des oxidativen Burst 
gekennzeichnet sind. Der fehlende Burst beeinträchtigt die antimikrobielle Aktivität der 
Phagozyten.  
60% aller CGD Patienten leiden an Mutationen des cybb Gens, welches auf dem X-
Chromosom vorliegt (X-CGD). 30% weisen eine Mutation des ncf1 Gens auf, welches das 
p47phox Protein kodiert. In einer kürzlich durchgeführten gamma (γ)-retroviralen Gentherapie 
(GT) Studie zur Behandlung von X-CGD konnten erste klinische Erfolge erzielt werden. 
Diese Therapieform ist eine Alternative zur Knochenmarktransplantation, die bei fehlendem 
HLA-identischen Spender häufig mit hoher Morbidität, Sterblichkeit und 
Transplantatversagen verbunden ist. Jedoch waren die retroviralen Gentherapie-Studien für 
X-CGD und ADA-SCID von klonaler Dominanz oder leukämischem Verlauf als Langzeitfolge 
von Transaktivierungsvorkomnissen begleitet.  
Eine Möglichkeit, die Risiken des Auftretens von Transaktivierung zu vermindern, ist der 
Gebrauch von γ-retroviralen selbst-inaktivierenden (SIN) Vektoren, bei denen die viralen 
Elemente (Promotoren- und Enhancersequenzen) während der Integration inaktiviert 
werden. Die Expression des Transgens wird von einem internen gewebsspezifischen 
Promotor angetrieben, der im Idealfall selbst keine Enhancer Aktivitäten besitzt und die 
Expression des Transgens auf terminal differenzierte Granulozyten/Monozyten begrenzt.  
Für die p47phox-defiziente Form von CGD ist die Knochenmarktransplantation die momentan 
einzig verfügbare Therapie. Deshalb liegt der Fokus dieser Doktorarbeit in der Entwicklung 
eines sicheren γ-retroviralen SIN GT Vektors, um den p47phox CGD Phänotyp zu korrigieren. 
Im ersten Teil der Doktorarbeit klonierten wir unterschiedliche myelospezifische 
Promotorkandidaten in γ-retrovirale SIN Vektoren, die die p47phox Transgenexpression 
antreiben. Die Konstrukte wurden auf myelospezifische Expression und funktionelle 
Wiederherstellung des oxidativen Burst in transduzierten hämatopoietischen Stammzellen 
überprüft, welche in der Zellkultur weiter zu Granulozyten ausdifferenziert wurden. In diesem 
Auswahlverfahren haben wir einen neuen erfolgsversprechenden myelospezifischen 
microRNA-223 (miRNA-223) Promotor gefunden, der die p47phox Expression auf 
Granulozyten begrenzte. Im Weiteren führte die miRNA-223 kontrollierte Expression zur 
funktionellen Wiederherstellung der NADPH-Oxidase in kultivierten Zellen.  
Im nächsten Schritt wurde dieser myelospezifische miRNA-223 Promotor in einer GT bei 
p47phox -/- Mäusen verwendet, und das Ergebnis wurde mit einem konstitutiv aktiven 
Kontrollvektor verglichen. Die GT mit diesem miRNA-223 Vektor zeigte eine klare 
myelospezifische p47phox Transgenexpression sowie eine intakte funktionelle NADPH-
Oxidase in den Zielzellen (Neutrophile) in vivo. Die beschriebene Kombination eines γ-
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retroviralen SIN Vektors mit einem strikten myelospezifischen Promotor zeigt bei der GT for 
CGD eine deutliche Verbesserung der Sicherheit der GT für CGD.  
Zu guter Letzt ist der Nachweis der p47phox Expression eine zwingende Anforderung für das 
Monitoring einer GT. Die intrazelluläre Immunfärbung des zytoplasmatischen p47phox 
Transgenprodukts interagiert allerdings mit der Analyse der Aktivität des oxidativen Burst. 
Um dieses Problem zu lösen, entwickelten wir erfolgreich ein neues Reportersystem. In 
diesem System wird das zytoplasmatische p47phox über die Koexpression eines zellulären 
Oberflächenmarker gemessen, der in einem 1:1 molaren Verhältnis exprimiert wird.  
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Summary 
Chronic granulomatous disease (CGD) comprises a group of primary immunodeficiencies 
characterized by the failure of respiratory burst and thereby an impaired antimicrobial activity 
of phagocytes. 60% of all CGD patients suffer from mutations in the X-linked cybb gene (X-
CGD), followed by 30% with a mutation in the ncf1 gene encoding p47phox. First clinical 
success could be achieved in a recent gamma (γ)-retroviral X-CGD gene therapy (GT) study. 
This GT represents a therapy complementary to bone marrow transplantation (BMT), which 
is associated with unacceptable high rates of morbidity, mortality and graft failure, except in 
very selected cases in which a HLA-identical donor is available. However, retroviral GTs for 
X-CGD and ADA-SCID were accompanied with clonal dominance or leucemic progression 
as long-term effects of transactivation events.  
One option to minimize the risks for transactivation in CGD GT is the use of γ-retroviral self-
inactivating (SIN) vectors, in which the viral promoter/enhancer elements are inactivated 
upon integration. The transgene expression is driven by an internal tissue-specific promoter 
element which ideally lacks enhancer activity and restricts transgene expression to terminally 
differentiated granulocytes/monocytes.  
For the p47phox-deficient form of CGD, BMT is the only therapy available at present. 
Therefore, the thesis focused on the development of a safer γ-retroviral SIN vector for gene 
replacement therapy to correct the p47phox CGD phenotype.  
In the first part of this thesis we cloned various myelospecific promoter candidates into γ-
retroviral SIN vectors driving p47phox expression. The constructs were screened for 
myelospecific expression and functional reconstitution of the NADPH oxidase in transduced 
murine p47phox -/- hematopoietic stem cells upon propagation to granulocytes in cell culture. 
By this screen we have identified a new potent myelospecific promoter, microRNA-223 
(miRNA-223), which results in p47phox expression exclusively in granulocytes. Furthermore, 
miRNA-223 controlled p47phox expression resulted in functional reconstitution of the NADPH-
oxidase in cell culture. 
Next, this myelospecific miRNA-223 promoter was utilized in an in vivo GT in  
p47phox -/- mice and the outcome was compared to the constitutive active control vector. GT 
with miRNA-223 vector resulted in a clearly myelospecific p47phox transgene expression and 
restored the function of the NADPH oxidase in target neutrophils in vivo. The presented 
combination of a γ-retroviral SIN vector with a strictly myelospecific promoter represents a 
major safety improvement in CGD GT. 
Finally, the detection of p47phox expression is a mandatory requirement for GT monitoring. 
Intracellular immunostaining of the cytoplasmic p47phox transgene product interferes, 
however, with the analysis of respiratory burst activity. To overcome this limitation we 
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successfully developed a new reporter system for measuring cytoplasmic p47phox by co-
expression of a cellular surface marker in a molar ratio of 1:1. 
 VII
 General Introduction 
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Chapter Overview 
The central issue of this work was to develop a safe retroviral-mediated gene therapy (GT) 
for the p47phox deficient form of Chronic Granulomatous Disease (CGD). Therefore, the first 
part focuses on the description of CGD. Underlying mechanisms causing CGD, the main 
clinical features and currently available treatment options for CGD, especially GT, are 
described including the risks of current retroviral GT protocols. The second part summarizes 
basics about the biology of hematopoietic stem cells (HSC) and hematopoiesis, since HSC 
are the prime target organ of CGD GT. The last part illustrates basic features of retroviruses 
and their use as vehicles for gene transfer. Furthermore, a viral system for co-expression of 
two proteins is introduced.  
 
CGD 
General description of CGD 
CGD is a rare primary inherited immunodeficiency leading to severe and life-threatening 
bacterial and fungal infections. CGD is normally diagnosed in infancy and has an incidence 
of between 1:200000 and 1:250000 live births1. The disease is caused by deletion/mutations 
in any one of the four gene encoding the subunits of the superoxide-generating reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex in phagocytic cells 
(neutrophils, monocytes, macrophages and eosinophils). The NADPH oxidase is elementary 
for microbial killing by reducing molecular oxygen to superoxide, which subsequently reacts 
to form secondary reactive oxygen species (ROS)2. Thus phagocytic cells from CGD patients 
with absent or malfunctioning NADPH oxidase subunits are able to phagocytose pathogens 
but are unable to kill them (figure 1). As a result, affected individuals suffer from recurrent 
life-threatening bacterial and fungal infections. Abnormally exuberant inflammatory 
responses of CGD patients can lead to formation of inflammatory granulomas to which CGD 
owes its name1, 3.  
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Figure 1 Transmission electron microscopy of opsonized Escherichia coli  (E.coli) strain ML-35 2.5 h after phagocytosis by 
healthy control (A) or CGD (B) granulocytes. Black arrow denote undigested E. coli inside the phagocytic vacuole. White arrow 
indicate E. coli degradation. Insert on the right upper corner shows magnifications of digested (A) and undigested (B) bacteria. 
Scale bars 2 µm (modified from4). 
 
The NADPH oxidase: Function and properties 
NADPH oxidase is found in professional phagocytes (neutrophils5, eosinophils, monocytes 
and macrophages6). It is a phagosomal and plasma membrane-associated enzyme complex. 
The structure of the NADPH oxidase is complex (figure 2) consisting of two membrane-
bound elements (gp91phox and p22phox) and three cytosolic components (p67phox, p47phox and 
p40phox)7, 8. The names of the oxidase subunits are referred to their apparent molecular mass 
(kDa) and have been given the signation phox, for phagocyte oxidases9. In table 1 properties 
of the phox components are summarized. In addition, the low-molecular weight GTP-binding 
protein (either Rac 1 or Rac 2) associates with and is involved in the regulation of the 
NADPH oxidase10, 11.  
The multicomponent enzyme harbours a redox center that transfers electrons from 
cytoplasmic NADPH onto extracellular (or intraphagosomal) molecular oxygen thereby 
generating superoxide according to the following reaction7, 12: 
 
NADPH + 2O2 → NADP+ + H+ + 2O2 -
 
The electron transfer from NADPH to oxygen is a multistep process. gp91phox and p22phox 
form a membranspanning flavo-hemeprotein, called flavocytochrome b558, containing two 
molecules of heme and one molecule of flavin adenin dinucleotide (FAD) through which the  
electrons are transported sequentially8. NADPH cannot bind to flavocytochrome b558 unless 
the complete enzyme has been assembled during activation, and only then electron transfer 
actually takes place (figure 2b).  
The soluble regulatory components p47phox, p67phox and p40phox are found within the cytosol 
in resting cells9, 13. Phagocyte activation leads to phosphorylation of cytosolic factors (p47phox, 
 3
Figure 2 A model of phagocyte NADPH oxidase (‘respiratory burst’) activation. (a) In its resting state the oxidase is composed of 
membrane-bound and cytosolic protein components. The integral membrane proteins gp91phox and p22phox together form the 
flavocytochrome b558, with the larger subunit containing the FAD and heme- (Fe) binding sites. The cytosolic components 
include p40phox, p47phox and p67phox, which exist together in a 290 kDa complex. In its inactive GDP-bound state, the small GTP-
binding protein Rac is also cytosolic and is bound to Rho GDP-dissociation inhibitor (RhoGDI). (b) Upon activation p47phox, 
p67phox and p40phox become stably associated with the plasma membrane primarily through interactions between p47phox and the 
subunits of flavocytochrome b558. This translocation process is accompanied by, and perhaps requires both the release of Rac 
from RhoGDI, its conversion to an active (GTP-bound) state and its association with the plasma membrane, and the 
phosphorylation of p47phox (at multiple sites), p40phox and p67phox. In a manner that is not yet fully understood, binding of the 
cytosolic components activates the flavocytochrome to catalyze the transfer of electrons from NADPH to oxygen, via the flavin 
and heme redox centers in gp91phox, to form O2- (red dashed line). The compartment labeled ‘inside’ is the cytoplasmic space; 
‘outside’ refers either to the extracellular or phagosomal space (modified from13).  
 4
p67phox, p40phox, Rac) and to their translocation to the membrane. There, p47phox and p67phox 
bind to flavocytochrome b558 and build up the activated NADPH oxidase complex.  
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 flavocytochrome b558  
 gp91phox p22phox p47phox p67phox p40phox
Gene and locus cybb; Xp21.1 cyba; 16q24 ncf-1; 7q11.23 ncf-2; 1q25 ncf-4; 22q13.1 
Amino acids 570 195 390 526 339 
Molecular weight:      
 Predicted 65,338 Da 20,959 Da 44,684 Da 59,735 Da 39,039 kDa 
 By SDS-PAGE ~90 kDa 22 kDa 47 kDa 67 kDa 40 kDa 
Glycosylation Yes No No No No 
pI 9.26 10.1 9.58 6.12 7.28 
Phosphorylation No Minor Yes Minor Yes 
Location in neutrophil      
 Resting Membrane of specific granule and 
plasma membrane 
Cytosol 
 Stimulated Plasma membrane 
and phagosomal membrane 
Membrane associated 
Abundance pmol/106
cells (cytosol conc.) 
1.0–2.0 6.0 (2750 nM) 1.0 (460 nM) 1.0 (460 nM) 
Functional domains 
 
C-terminus binds 
cytosolic components. 
Heme, FAD and  
NADPH 
binding regions 
C-terminal 
proline-rich 
region 
Phosphorylation sites 
PX domain, 2 SH3 
domains, proline-rich 
region 
Tetratricopeptide 
repeat, 2 SH3 
domains, proline-
rich 
domains 
PX and SH3 
domains, 
octicosapeptide 
repeat 
Table 1 Properties of the phagocyte respiratory burst oxidase (phox) components (modified from8) 
 
The superoxide produced by electron transfer of NADPH oxidase itself contributes by only 
50% to the bactericidal activity14. Within the phagosome, superoxide is spontaneously or 
enzymatically converted into hydrogen peroxide (H2O2), which may then react further to toxic 
compounds such as hydroxyl radicals OH-, hypochlorous acid catalyzed by 
myeloperoxidase2 and peroxynitrite7 (figure 3).  
 
2O2- + 2H+ → O2 + H2O212
 
Although superoxide derivatives were first believed to be solely responsible for the 
antimicrobial activity of phagocytes, new insights have revealed additional mechanisms of 
the NADPH oxidase2. The NADPH oxidase induces killing in an indirect way via liberation of 
microbicidal azurophil granule proteases (cathepsin G and elastase) into the phagosome. 
Segal et al15 have seen that mice deficient in the granule proteases cathepsin G and 
elastase are ineffective to eliminate Staphylococcus aureus (S. aureus) and Candida 
albicans (C. albicans), even though they had normal NADPH oxidase activity. Moreover, 
protease inhibitors could impair the ability of human neutrophils to kill S. aureus. Based on 
these results, they proposed a new model for microbial killing in neutrophils2 (figure 3). The 
NADPH oxidase drives an electrogenic process by transferring large amounts of electrons 
into the phagocytic vesicle. The compensation of enzymatic charge separation is still a 
matter of debate.  
Segal and coworkers developed a model in which the charge transfer is partly compensated 
by the influx of protons (H+) from the cytosol through the NADPH oxidase2. The phagosomal 
membrane depolarization and maybe a drop of pH just beneath the plasma membrane 
elevate cytosolic calcium (Ca2+) concentrations which fully open calcium2+-activated K+ (BKca) 
channels16. The influx of potassium (K+) partly elevates the pH in vesicle and most 
importantly leads to a hypertonic environment.  
On the other hand, the latest models claim that charge separation is compensated by 
voltage-gated proton channels and not by the BKca channels17-19.  
The change of intraphagosomal pH and ion composition results in the liberation and 
activation of granule proteases and antimicrobial peptides2, 15. The functional role of NADPH 
oxidase in antimicrobial peptide processing and activity is not clear so far.  
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Figure 3 In the “belly” of the phagocyte (according to the model of Segal). Within the small space between an ingested 
bacterium (shaded area) and the membrane of the phagosome, a number of chemical reactions take place which lead to 
bacterial killing by neutrophils (see text for detail; modified from20). 
 
Since the discovery of the indirect killing mechanisms, the open question still remains, if the 
oxidative products are directly involved in microbial killing7, 20. Segals et al argue2, superoxide 
generation is needed only to increase the ionic strength within the phagosome, which then 
allows solubilization of the proteases and does not contribute directly to the killing process. In 
others view9, 20, 21 there is a large body of evidence that oxidants are involved directly in 
killing. For example, CGD neutrophils are able to kill catalase-negative bacteria (which 
excrete H2O2) and also catalase-positive bacteria, if they coingest glucose oxidase, which 
generates H2O222-24. Recently ex vivo differentiated neutrophils from CD34+ stem cells with 
deficient phagosomal granule development showed significant reduced killing activity against 
E. coli in comparison to peripheral blood neutrophils, but could still kill 50% of E. coli 14. 
These findings point to a direct contribution of ROS in the killing process.  
In addition to active phagocytosis and intracellular killing by antimicrobial peptides and ROS, 
neutrophil extracellular traps (NET) were found to be involved in extracellular microbial 
killing25. In NET mediated killing, a complex of granule proteases, antimicrobial peptides and 
chromatin-DNA is supposed to kill trapped bacteria and fungi. NETs are released upon a 
specialized form of cell death that is NADPH oxidase dependent26.  
 
Molecular genetics of CGD 
More than two-thirds of all CGD cases result from mutations in the X-linked cybb gene 
encoding the gp91phox subunit (X-CGD), followed by autosomal recessive forms of CGD: 30% 
of all CGD cases are associated with mutations in the ncf-1 gene encoding p47phox, while 
only 5% of cases are due to mutations in cyba (p22phox), and ncf-2 (p67phox)1, 13. A single 
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patient with heterozygous mutation in the rac 2 gene was identified27, 28 with a CGD 
phenotype. CGD cases due to mutations in ncf-4 encoding p40phox have not yet been 
reported7. 
Heyworth and coworkers13 summarized 410 defects in the four affected genes. Only 19 
resulted in a normal level of inactive or weakly active protein. The remaining 95% of CGD 
mutations resulted in a complete absence or greatly diminished level of protein, either 
because the affected gene is partially or completely deleted, or because the aberrant protein 
product or mRNA is unstable.  
Mutations in ncf-1 encoding p47phox cause the most common autosomal recessive form of 
CGD. Unlike the other variants of the disease, in which a high degree of heterogeneity exists 
among mutations, a single mutation has been identified in about 94% of affected alleles in 
patients with p47phox deficiency13. This mutation is a base deletion of gt at the beginning of 
exon 2 that causes a frameshift resulting in a premature stop codon29. This gt deletion is the 
key difference between ncf-1 and a pair of highly homologous pseudogenes that are 
physically close to the functional gene. Two studies have shown that the predominance of 
the gt deletion probably happens during recombination events (crossover) between the 
functional ncf-1 and its highly homologous pseudogene30, 31. 
 
Clinical features of CGD 
CGD patients suffer from severe recurrent bacterial and fungal infections of body surfaces, 
e.g. the skin, the airways, the gut and draining lymph nodes. Through contiguous and 
haematogenous spread also many internal organs can be affected e.g. the liver and the 
bones. The major clinical manifestations of CGD are pyoderma, pneumonia, inflammation of 
the gastrointestinal tract, lymphadenitis, liver abscess and osteomyelitis1, 3. Many CGD pa-
tients also develop chronic inflammatory granulomas, which are distinctive hallmark of this 
disorder. Mechanistically the formation of granulomas is believed to reflect a dysregulated 
inflammatory response and/or inefficient degradation of inflammatory mediators in the 
absence of respiratory burst-derived oxidants32.  
S. aureus is the pathogen most frequently found in CGD patients. Aspergillus species or 
Burkholderia cepacia are the most common cause of death in these patients, contributing 
towards an overall death rate of 2% (for autosomal CGD) and 5% (for X-CGD)1 per year. 
Other pathogens that are frequently found in insolates from CGD patients include Nocaria 
species, and a variety of Gram-negative enteric bacilli such as Serratia marcescens, 
Salmonella species.  
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Mouse models of CGD  
Four different CGD mouse models have been characterized: mouse models resembling the 
gp91phox deficient CGD33, the p47phox deficient CGD34, the p22phox deficient CGD35 and 
deficient p40phox CGD36. CGD mice have abnormalities in both host defense and 
inflammation which are similar to their human counterpart. CGD mice show also an increase 
in susceptibility to the opportunistic pathogens, Burkholderia cepacia and Aspergillus 
species, two organisms that are particularly problematic in CGD patients. Other organisms, 
e.g. S. aureus, Salmonella typhimurium, Mycobacterium tubercolosis and Candida species 
show increased virulence in both, CGD mice and in CGD patients33. Both gp91phox - and 
p47phox  deficient CGD mice have abnormalities in inflammatory responses9. For example 
gp91phox-/- mice exhibit an exaggerated acute inflammatory response after instillation of 
sterilized hyphae into the lung or upon intradermal injection, which evolves into a chronic 
granulomatous infiltrate32.  
 
Treatment of CGD 
Conventional management 
CGD patients need to be instructed about their condition and its management, and checked 
regularly by experienced physicians. They should as far as possible reduce exposure to 
potentially infectious agents. They require prophylactic antimicrobial therapy which consists 
of lifelong prophylaxis with antibiotics such as trimethoprim/sulfomethoxazol (cotrimaxole). 
This antibiotic has a broad activity against Gram-negative bacteria and is concentrated inside 
host cells3. For antifungal prophylaxis the lipophilic itraconazole is taken, because it displays 
high activity against Aspergillus spp. A subgroup of “variant” X-linked CGD patients, who 
have some residual respiratory burst activity through possessing splice site mutations, can 
be treated with interferon-gamma (IFNγ), a macrophage-activating cytokine produced by T 
cells and natural killer cells37, 38. IFNγ  improves splicing efficiency. Thereby a small amount 
of normal gp91phox transcript is generated, which leads to an increase in cytochrome b 
expression and normal killing activity in phagocytes of “variant” CGD patients. Acute 
infections in CGD patients are treated most successfully by prompt and prolonged therapy 
with the appropriate antibiotic therapy3. Additionally during severe infections the immune 
system can be temporarily supported by white cell transfusions, which is however, limited by 
the risk of antibody formation against foreign human leukocyte antigen (HLA). Overall, these 
prophylactic medications ameliorate the symptoms of the disease, as seen by improved 
health conditions and survival rates1. 
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Cure of the disease: Hematopoietic stem cell transplantation (HSCT) 
One option to cure CGD is hematopoietic stem cell transplantation (HSCT). The overall 
success rate of conventional HSCT (myeloablative marrow conditioning, HLA-identical donor 
material) is 81%, with an overall mortality of 15%39. Survival in these patients without 
infection at transplantation was excellent. Most cured patients had over 95% circulating 
donor cells and pre-existing infections and chronic inflammatory lesions have been cleared in 
all engrafted survivors. Therefore myeloablative marrow conditioning HSCT is a valid 
therapeutic option for children with CGD and having HLA-identical donor. Unfortunately a 
highly compatible donor is only available for 52% of CGD patients 40. The major risk factors 
associated with HSCT are graft-versus-host disease and inflammatory flare-ups at sites of 
infection. In the absence of a HLA-identical sibling or unrelated donor, haploidentical HSCT 
has been performed only twice and is considered rather risky because of delayed immune 
reconstitution and graft failure3. 
In vitro fertilization (IVF) combined with preimplantation HLA-testing to select an HLA-
genoidentical, disease-free sibling embryo as a “savior baby” for successful HSCT is another 
treatment option41 (not allowed in Switzerland). Beside legal and ethical concerns this 
demanding treatment needs a young maternal age and the firm wish of the parents to have 
another healthy child. Moreover, the probability of successful pregnancy in the most 
experienced IVF centers is only around 10%.  
 
Stem cell GT 
CGD is considered to be a suitable candidate for a GT approach: All genes encoding the 
subunits of the NADPH oxidase complex are known and are not involved in cell proliferation. 
Several assays are established to determine superoxide production after GT in order to 
estimate functional correction of the disease. Furthermore, functional correction of as few as 
5% of neutrophils should be sufficient to alleviate the symptoms of the disease based on the 
experience in X-linked CGD carriers42. These facts and observations have motivated to 
develop a GT protocol for CGD treatment.  
 
Preclinical studies of GT for CGD 
For the first time in 1992, retroviral GT restored respiratory burst activity in Epstein-Barr virus 
(EBV)-transformed peripheral blood CGD B-cells ex vivo 43. Later on, human CGD CD34+ 
progenitor cells or cells from the human gp91phox knockout cell line (PLB985 X-linked CGD) 
have been tested for the feasibility of GT. Beside retroviral vectors, an adeno-associated 
virus was successfully tested as well in immortalized CGD B cells44. In all cases respiratory 
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burst activity has been restored, albeit at different levels depending on the expression vector 
used in each experiment45-50.  
The availability of animal models for the two main forms of CGD had significant impact on 
preclinical CGD GT development. Respiratory burst activity was reconstituted in both 
gp91phox and p47phox mouse models in which the transplanted HSCs were transduced with 
gp91phox 50-52 or p47phox 53, 54 expressing vectors prior to reinfusion into lethally or sublethally 
irradiated recipients. Dinauer et al51 reported that 50% to 80% of granulocytes in X-linked 
CGD mice had a reconstituted superoxide activity and an intact host defense against 
Aspergillus fumigatus after GT. The use of improved retroviral vector backbones, like those 
derived from spleen focus-forming virus (SFFV) have further enhanced gp91phox expression 
in hematopoietic cells. Moreover, serial transplantations of transduced cells into secondary 
and tertiary gp91phox -/- recipients demonstrated even long-term correction of X-linked CGD55. 
The ectopic expression of gp91phox, which is normally only found in myeloid cells, was well 
tolerated, since transgene expression did not affect engraftment, survival, proliferation or 
differentiation of transduced cells in vivo50-52, 55, 56. The clearance of pathogens by gene-
transduced cells was checked by challenge experiments. In these experiments animals 
transplanted with gene-corrected cells or mixtures of CGD and wild-type cells were exposed 
to bacteria and fungi. It could be shown that the minimal protecting level of superoxide 
production varies depending on the pathogens used to challenge the animals. For example, 
for mice challenged with Burkholderia cepacia 30% gene-corrected cells were necessary, 
whereas against Aspergillus fumigatus spores only 11% gene-corrected cells were sufficient. 
Similar observations were made by subcutanous injection of sterilized Aspergillus fumigatus 
hyphae into X-linked CGD mice. These mice developed an acute and chronic inflammation 
with granuloma formation resembling that observed in CGD patients. Mice with more than 
20% gene-corrected cells were protected from granuloma formation, whereas lower 
transduction levels were still associated with chronic infections57. In 1997 the first retroviral 
GT for p47phox-deficient CGD was performed in p47phox -/- mice54. ScaI+ p47phox-/- marrow 
progenitor cells were transduced with a moloney murine leukemia virus (MLV)-based 
retroviral vector which encoded the human form of p47phox. Transduced progenitor- and 
stemcells were transplanted into moderately irradiated (500cGy), G-CSF preconditioned 
p47phox -/- mice. A portion of peripheral blood neutrophils (12% after 4 weeks, 2.6% after 14 
weeks) showed restored respiratory burst activity in a dihydrorhodamine 123 (DHR) assay. 
GT treated p47phox -/- mice showed significantly lower bacteremia levels and higher survival 
rate after challenge with CGD pathogen Burkholderia cepacia compared to untreated 
animals53.  
All together, these preclinical studies have pointed out, that also low superoxide levels and/or 
a small fraction of fully gene-corrected cells might already protect CGD patients from severe 
and life-threatening infections and improve the clinical status and quality-of-life of CGD 
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patients51-54, 57, 58. However, in cases where gene-transduced cells will not produce the same 
levels of superoxide as observed in wild-type cells, larger amounts of gene-corrected cells 
(30%) may be required for an effective antimicrobial activity57.  
 
Clinical gene therapy studies for CGD 
In 1995 the first clinical GT trial for p47phox deficient CGD was led by Harry Malech at the 
National Institutes of Health (NIH)59. Five p47phox deficient CGD patients were treated with 
granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood CD34+ cells after 
ex vivo transduction with a p47phox-expressing retroviral vector. A large number of transduced 
CD34+ cells (total numbers between 2 x 106 and 2 x 108) were reinfused into the patients 
without prior BM conditioning. The level of functionally corrected granulocytes was low 
(range between 0.004% and 0.05% of total peripheral blood granulocytes) and persisted at 
this level for up to 6 months after reinfusion. 3 years later the same research group initiated a 
second GT study for X-linked CGD. The protocol included several modifications: CD34+ cell 
mobilization was achieved using Flt3 ligand and G-CSF; retroviral transduction of CD34+ 
cells was done on four subsequent days, resulting in high rate of colony-forming cells (range 
between 48% and 89%). Furthermore, patients received transduced CD34+ in two cycles 50 
days apart, without BM conditioning. Despite these modifications, the level of cells with 
restored burst activity was still low (range between 0.2 and 0.6%) and persisted at this level 
for the following 4 to 6 months60. In 2004 a third clinical GT study for X-CGD was performed 
by Dinauer et al61, at Indiana University. In study number three, a murine stem cell virus-
derived retroviral vector was used for transduction. Again, without prior BM conditioning after 
reinfusion only 0.1% of peripheral blood neutrophils showed restored respiratory burst 
activity for almost 9 months.  
In summary, the first clinical GTs provided evidence that the GT approach to treat CGD is 
feasible. Retrospectively the low level of corrected cells can be explained by the lack of BM 
conditioning. Gene-transduced CGD cells are not expected to have a proliferative advantage 
over non transduced cells. Engraftment of a sufficient high number of HSCs to provide long-
term correction is probably only possible when BM conditioning is performed or when a 
resistance gene is co-expressed to allow for in vivo selection. In animal studies sufficient 
gene marking associated with expression at therapeutically relevant levels in both lymphoid 
and myeloid lineages after GT could only be reached if the protocols contained non-
myeloablative conditioning62, 63, myeloablative conditioning52, 53, 55, 57, sub-myeloablative or 
chemotherapy doses 64, 65.  
The first human clinical GT trial for X-CGD with BM conditioning was performed by the group 
of M. Grez, in Frankfurt, Germany, reviewed by66. In this study, one X-linked CGD patient got 
a mild myelosuppressive conditioning regimen (cyclophosphamide 1g/m2/day on four 
consecutive days) prior to reinfusion of transduced cells. A bicistronic vector containing 
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gp91phox cDNA and a marker gene encoding a cytoplasmic truncated form of the human low-
affinity nerve growth factor receptor (∆LNGFR) was used. Despite a high transduction 
efficiency (44%) in G-CSF-mobilized peripheral blood CD34+ cells the engraftment of gene-
transduced cells was still minimal (1% of the peripheral blood granulocytes after reinfusion, 
stable for 3 months). Possibly the immunosuppressive drug cyclophosphamide was not 
sufficient to generate niches in BM and to allow engraftment of cells.  
Then, GTs for the correction of severe combined immunodeficiency (SCID)-X1 and 
adenosine deaminase (ADA)-SCID successfully addressed the topic of engraftment67, 68. 
These studies showed proof-of-principle for the correction of immunodeficiencies by GT. At 
the same time the SCID-X1 study revealed limitations and risks associated with this new 
technology. The outcome of the ADA-SCID GT was particular relevant for future CGD 
studies, since BM conditioning was used for the first time to improve engraftment and 
survival of gene-transduced cells67. The two patients enrolled in this study67 received 
busulfan (2mg/kg/day) for 2 days before infusion of transduced cells. Busulfan is a 
chemotherapeutic drug, which is well tolerated and widely used in pediatric patients receiving 
HSCT69. The busulfan treatment resulted in high and long-time engraftment (Patient 1: 10% 
gene-marked cells in CD34+ progenitor cells 1 year after injection), in an increase in 
lymphocyte counts and in improved immune functions and clinical status.  
Most relevant with regard to CGD GT studies was the achievement of substantial amounts of 
gene-marked myeloid cells, e. g. granulocytes.  
The outcomes of the two SCID GT studies paved the way for a new GT study for X-CGD 
which was performed in Frankfurt/Zurich in two patients in 20054. Two modifications in the 
GT protocol were included: First, improved gene transduction protocol by using high 
concentrations of Flt3 ligand and stemcell factor in combination with thrombopoietin and IL-6 
on retronectin-precoated culture bags. Second, BM conditioning by busulfan for better 
engraftment of gene-transduced cells. A monocistronic γ-retroviral vector encoding gp91phox 
(SFgp91phox) was used to transduce CD34+ cells which were isolated by G-CSF 
mobilization from peripheral blood of patients. Before reinfusion of transduced cells, 
myeloablative conditioning of BM was performed by busulfan (4mg/kg/day). The outcome of 
this GT was successful: For the first time high levels of gene marked neutrophils (range from 
12% to 31% of gp91phox positive blood granulocytes 4 to 5 months after GT) could be 
detected. Up to day +120 comparable amounts of functionally corrected neutrophils were 
measured in functional assays in both patients. Refractory bacterial and fungal infections 
from which patients had suffered for many years were cleared after GT. Surprisingly, an 
increase in the number of gene-corrected cells of up to 50 to 60% of all peripheral blood 
granulocytes was observed in both patients starting 5 months after transplantation and 
remained at this level. The overall myeloid cell proliferation was not affected by this increase, 
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so the granulocyte numbers remained constant as before GT. Retroviral integration sites 
(RIS) in the expanded cell population were analyzed by linker adapter-mediated polymerase 
chain reactions (LAM-PCR). Integration hot spots were found in three growth-promoting 
genes, namely mds1-evi1, prdm16, setbp1. The activation of these three genes raises 
concerns about possible occurrence of uncontrolled proliferation, abnormal hematopoiesis 
and eventually leukemogenesis in such cell clones. One of these hot spots, evi1 (ecotropic 
viral integration 1 site) encodes a transcription factor (TF) with a role in both self-renewal and 
transformation of HSCs. Constitutive overexpression of evi1 in murine BM cells induces a 
fatal pancytopenia with hypercellular BM and peripheral cytopenia. These features resemble 
those reported in the human evi1-positive myelodysplastic syndrome (MDS). However, none 
of the animals progressed to acute leukemia and the death of the animals was attributed to 
pancytopenia70. Evi1 overexpression itself is insufficient to induce acute myeloid leukemia 
(AML). The progression from MDS to AML requires additional genetic events. Watanabe-
Okochi and coworkers71 recently identified a mutation in aml1 which collaborates with evi1 
overexpression to induce MDS/AML in mice. In human, the evi1 overexpression is 
associated with poor survival of AML72, 73. However, mice experiments have revealed that 
single mds1-evi1 integrations resulted in long-term in vivo clonal dominance without turning 
leukemic74. Moreover, in a nonhuman primate gene-marking study, the mds1-evi1 gene was 
found to be a common integration site (CIS) with long-term clonal activity without clonal 
expansion and signs of leukemia75. Moreover, immortalized myeloid progenitor cell lines with 
RIS in evi1, prdm16, setbp1 did not engraft or result in leukemia in irradiated mice76. BM cells 
isolated from the patient 1 of this X-CGD gene therapy study did not show malignant 
transformations. The BM cells of the patients were strictly dependent on cytokines for growth 
and did not engraft in xenograft animal models4. Nevertheless, the proliferative stress caused 
by overexpression of mds1/evi1 or prdm16 in hematopoietic progenitor cells may cause 
further mutations that might develop into a malignant hematopoiesis. A long-term follow-up of 
treated X-CGD patients must be done to draw conclusions on efficacy and safety of this 
procedure.  
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Risks of retroviral GT: Insertional mutagenesis and its 
consequences 
For a long time the integrations of retrovirus and retrovirus-based vectors was believed to be 
distributed randomly throughout the genome. A malignant outcome of single insertions in the 
context of clinical settings was considered to be extremely unlikely77. However, first 
published reports of serious adverse events (SAEs) in retroviral GT studies changed this 
view completely78-80. SAEs were for the first time observed in an otherwise successful clinical 
GT trial in the X-SCID study. Three years after successful correction of SCID-X1 two patients 
suffered from uncontrolled lymphoproliferation or in clinical terms from lymphoblastic 
leukemia. The uncontrolled lymphoproliferation resulted from clonal T-cell expansion as a 
consequence of retroviral insertional activation of the lmo2 gene, which was previously 
implicated in de novo acute lymphoblastic leukemia81. Gene transfer vectors had based on 
the MLV which were used clinically to transduce HSC since the early 1990s82. 
Baum et al. discussed in several interesting reviews the chances and risks of retroviral GT, 
especially in a hematopoietic setting79, 80, 83, 84. For the first time they discussed side-effects 
which could occur by performing genetic manipulations in HSCs. Three side-effects are 
summarized in the following: 
1. Selective loss of long-term HSC properties: For genetic modification by viral transduction, 
HSCs have to be cultured and enriched ex vivo. The physiological proliferation of HSCs in 
BM is known to be slow. Since the efficiency of γ-retroviral gene-transfer is cell cycle 
dependent, HSCs need to be stimulated by a cocktail of cytokines to induce proliferation. 
This ex vivo culture harbors the danger of a selective loss of long-term HSC properties. 
Present attempts to optimize the culture conditions focus on the cytokine cocktail and the 
reduction of the culture period.  
2. Genotoxicity: Genotoxicity rising from transgene insertions, called insertional mutagenesis, 
are one feature of all stable gene transfer methods. Retroviral insertion has been studied in 
great detail (see below). The incidence of SAEs after retroviral insertions have been 
previously estimated to be rather low (between 10-6 and 10-8 per insertion event). However, 
based on the hypothesis of a semirandom choice of target sequence for retroviral integration, 
proto-oncogenic activation by RIS would be expected to be more frequent (10-2 and 10-3 per 
insertion event within 10 kb of a potential proto-oncogene)79. But several biological filters 
lower the risk of such insertion events from being directly cancerogenic. RIS are mostly 
monoallelic which reduces the risk for mostly recessive mutational events. RIS could lead to 
signal alterations which reduce the probability of survival of affected cell clone by triggering 
differentiation, apoptosis or impeding engraftment. A single mutation is normally not sufficient 
to develop a malignant phenotype. To promote uncontrolled proliferation of transformed 
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clones, several cooperating genetic mutations and environmental stimuli are required as 
observed in clinical and experimental findings of cancer development. For example, induction 
of leukemia is often caused by cooperation of at least two genetic alterations: one disturbing 
differentiation, another promoting proliferation. Thus, there must be a distinction between the 
frequency of insertional hits in (vicinity of) cellular growth regulatory genes, the frequency of 
functional gene alterations after insertional mutagenesis, and the frequency of insertional 
oncogenesis. In general, SAEs have been observed under conditions of high multiplicity of 
infection. From that point of view, SAEs by retroviral integrations can be markedly reduced 
by transfer of not more than 1 (or 2) transgenes per cell. The specific type of retroviral vector 
(backbone) utilized for gene-transfer influences the risk to activate neighboring cellular 
sequences. The long terminal repeat (LTR) of conventional retroviral vectors with its strong 
promoter and most relevant enhancer activities and the relatively weak polyadenylation 
signal can activate cellular sequences located downstream of the transgene insertion site. 
Therefore vector types with deleted enhancer elements after integration are likely to reduce 
the risk of activation of adjacent genes after integration.  
3. Immune response: SAEs can also occur by innate or acquired immunity against vector 
components or gene-modified cells. Especially in nonmyeloablative conditioning the 
tolerance could be incomplete. For example a GT approach to correct hemophilia B in mice 
by using a lentiviral vector encoding coagulation factor IX resulted in priming of an anti-F.IX 
immune response and rapid clearance of gene-modified cells85.  
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HSC and hematopoiesis 
Definition of HSCs 
HSCs are by definition clonogenic cells which possess the ability to self-renew and the ability 
to differentiate into mature blood cells of all lineages. By these abilities they contain the 
capacity to regenerate the whole blood system for a lifetime of an organism.  
 
Murine HSC and hematopoiesis 
The Weissmann group first characterized HSCs in the murine system as cells that do not 
express any lineage specific antigens (Lin- cells), that are positive for the stem cell 
associated antigen (ScaI), and express low amounts of T-cell antigen Thy-186. In later 
experiments, mouse HSCs were characterized as Lin-ScaI+c-kit+ (LSK) cells, which can be 
further distinguished in clonogenic longterm self-renewing HSCs (LT-HSCs), transiently self-
renewing HSCs (short-term HSCs) and non-self-renewing multipotent progenitors (MPPs)87. 
Downstream of the LSK compartment, cells loose their multipotent features and become 
lineage progenitors. The developmental abilities of these progenitors are either restricted to 
the myeloid lineage, designated as common myeloid progenitors (CMPs) or to the lymphoid 
lineage, designated as common lymphoid progenitors (CLPs), respectively. CLPs can further 
differentiate to T-lymphocytes, B-lymphocytes and natural killer (NK) cells, whereas CMPs 
can progress to granulocytic cells (neutrophils, eosinophils, basophils), monocytes, 
macrophages, erythrocytes and megakaryocytes88 (figure 4). From the discovery of CMPs 
and CLPs it was concluded that at this developmental stage all hematopoietic cells become 
either restricted to the myeloid or lymphoid development88. However, cells with lymphoid 
developmental capacities have been found to possess the capacity to give rise to 
granulocytes or macrophages (reviewed by89). Cells with these abilities do not fit into the 
classical hematopoietic model (figure 4). From these observation it was concluded that there 
are alternative developmental pathways. An alternative scenario would be that cells which 
were once committed to a certain lineage are not necessarily determined and might still 
retain some developmental flexibility. 
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Figure 4 Classical model of hematopoiesis: All blood cells originate from a common longterm self-renewing HSC. HSCs can be 
subdivided into LT-HSCs, short-term HSCs and non-self-renewing MPPs. They give rise to CLPs and CMPs. CLPs mature to B-
lymphocytes, T-lymphocytes and NK cells, whereas CMPs propagate to granulocytic cells (neutrophils, eosinophils, basophils), 
monocytes, macrophages, erythrocytes and megakaryocytes. ErP, erythrocyte precursor; MEP, megakaryocyte erythrocyte 
precursor (modified from 88).  
 
Hematopoietic lineage specification 
Although HSCs have been investigated most intensively, the nature of factors which drive 
HSCs either to self-renewal or differentiation remains largely unknown. Both uncontrolled 
expansion as well as loss of stem cells would be fatal for multicellular organisms. Two 
observations indicate that the development of HSCs is orchestrated by a combination of 
extrinsic and intrinsic signals. First, HSCs have been found to be regulated by specialized 
microenvironments, the hematopoietic niches. In the endosteum of the BM osteoblasts are 
regulating key elements (influence stem cell function through notch signaling pathway) and in 
vascular niches (found in the spleen and BM) sinusoidal endothelial cells play a pivotal role90. 
Second, HSCs and hematopoetic progenitor cells were reported to have the ability to divide 
asymmetrically91. During asymmetric cell division cells are polarized and localize specific 
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molecules to distinct regions of the cell, which are then transmitted unequally to the 
daughter-cells.  
The combination of these extrinsic and intrinsic signals is believed to alter the genetic 
program of the corresponding hematopoietic cells. Baum et al92 simplified the developmental 
hierarchy of hematopoiesis to three levels: a first level containing the long-lived multipotential 
stem cells with multilineage expression at low level, reduced metabolic activity, mainly in the 
G0 phase of the cell cycle, ready for activation of proliferation and differentiation; a second 
level of continuous differentiating progenitor and precursor cells with high metabolic activity, 
fast cell cycle, high de novo synthesis of RNA, increasing number of genetic loci irreversibly 
inactivated upon differentiation; a third level of mature cells in blood, lymphoid organs and 
tissues with short half-live (e.g. granulocytes, red cells and platelets) or upon activation re-
entering cell cycle and persisting for long-time (e.g. macrophages, mast cells, lymphocytes), 
with no de novo RNA synthesis or restricted to lineage-specific genetic programs.  
 
Human HSC 
BM was transferred already in the early 1960s to restore the blood system in 
immunocompromised patients. However, it is difficult to characterize defined cell populations 
within BM containing true HSC activity in humans. For ethical reasons human cell fractions 
cannot be tested experimentally whether or not they contain HSCs or more mature 
progenitor cells that are able to mediate longterm engraftment (reviewed by89). Nowadays, 
knowledge about human HSCs is mainly gained by xenografts experiments in NOD-SCID 
mice. The most primitive human hematopoietic cells are characterized by Lineage negative 
(Lin-) CD133+ CD34- CD38- CD33-93 further progressing to Lin- CD34+ CD38- CD90+ 
CD45RA-expression94, 95. A down regulation of CD90 was reported as marker for a reduced 
self-renewal potential. The cells are able to restore longterm hematopoiesis, but show a 
significant reduction in engraftment. The next developmental step is then the upregulation of 
CD45RA. These cells are unable to restore human hematopoiesis in mouse.  
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Native retroviruses 
General description 
The family of retroviridae are divided in three subfamilies: oncoviridae, lentiviridae and 
spumaviridae. The retroviral life cycle is characterized by transcription to single stranded 
RNA (ssRNA), packaging of two ssRNA molecules into one infectious particle, the reverse 
transcription into DNA and integration into the target genome. Retroviral particles contain 
three proteins with enzymatic activity: the reverse transcriptase (RT); the viral integrase (IN), 
(that catalyzes the insertion of the viral DNA into host cell DNA) and the viral protease (PR) 
which cleaves at specific site to produce mature virion proteins. Most retroviruses from 
oncoviridae (alpha-, beta-, and gammaretrovirus) contain defined simple genomes encoding 
only three genes common to all retroviruses (figure 7): pol, which encodes the enzymes (RT, 
associated RNase H and IN), gag (group-specific antigen gene) which encodes proteins of 
the viral core (matrix and capsid proteins) and env which encodes the viral transmembrane 
envelope. Envelope proteins determine the host cell specificity. Their classification into 
ecotropic, xenotropic and amphotropic strain originated from early reports on virus replication 
in cell culture96. Mice-tropic or ecotropic strains replicated only in culture of mouse and rat 
cells. MLV strains that replicated not in mouse cells but in cultures derived from other 
species were called xenotropic strains. The third group, the amphotropic MLVs have general 
host range characteristics of both mouse and xenotropic viruses.  
 
Retroviral life cycle 
The retroviral life cycle follows the general pathway of enveloped viral infections (figure 6). 
However, since the viral genome consists of ssRNA, the genetic information must be 
transferred into double-stranded DNA (dsDNA) before integration can take place (see 
textbooks for more details, e.g.97, 98).  
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Figure 6 Retroviral life cycle. The cycle is initiated by adsorption of the viral envelope to a specific receptor at the surface of the 
host cell. After fusion with the plasma membrane, the viral capsid or core enters the cell and the RNA genome is reverse 
transcribed into viral dsDNA which passes the nucleus and integrates into the host genome. The viral DNA serves as template 
for RNA molecules encoding the necessary viral proteins and progeny RNA packaged into new particles. The assembly and 
release by budding occurs at the cell membrane and fully infectious particles are generated by proteolytic maturation (modified 
from97).  
 
In this study retroviral vectors derived from MLV were used for gene transfer. Therefore the 
retroviral MLV genome is introduced in the following section. 
The coding sequences are flanked by LTR. LTR contain several transcriptional control 
elements: promoter, enhancer, polyadenylation signals and sequences involved in replication 
and integration (figure 7). The U3 region includes the promoter and multiple enhancer 
sequences which interact with cellular transcriptional activator proteins. Transcription initiates 
at the boundary between U3 and R and the site of poly-adenylation is found at the boundary 
between R and U5. The (+)-DNA-strand initiation site is called polypurine-tract (PPT), 
whereas (-)-DNA-strand initiation site is called primer binding site (PBS). ψ signal region is 
responsible for packaging of viral RNA into capsid. The Gag and Pol proteins are first 
translated as polyprotein precursors from the full length transcript and afterwards cleaved to 
mature proteins by PR. In contrast, the envelope polypeptide is translated from spliced 
genomic transcript and further processed by cellular host enzyme machinery.  
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Figure 7 Proviral genome of retroviruses (e.g. MLV). The LTR includes promoter and enhancer regions (U sequences unique to 
the 5’ (U5) or 3’ (U3), repeat region (R)). Polyadenylation site (poly A) site lies within the 3 ’LTR between R and U5 region. The 
shown cis-acting elements are tRNA primer binding site (pbs), the splice donor site (SD), the packaging signal (ψ) and the PPT. 
The shown trans-acting elements are the coding regions group-antigen specific gene (gag), protease gene (pro), polymerase 
gene (pol) and envelope gene (env).  
 
Other retroviruses, like the HIV-1 lentivirus, have more complex genomes which include 
additionally auxiliary or accessory genes encoding non structural proteins98. These 
accessory proteins affect viral gene expression and/or pathogenesis. 
 
Replication and integration of retroviral genome 
After the capsid is released inside the host cell, viral RNA is reversely transcribed in double 
stranded DNA-RNA chimera and further processed to dsDNA. This reverse transcription is a 
complex process in which the (-)-strand DNA and afterwards the (+)-strand DNA is 
synthesized by RT98. The produced viral dsDNA forms a complex with viral-encoded 
integrase and other proteins (preintegration complex (PIC)). This PIC is transported from the 
cytoplasm into the nucleus. Mechanisms mediating nuclear import of retroviral genomes are 
poorly understood99. It is known that γ-retroviruses like MLV and lentiviruses like HIV-1 enter 
the nucleus by different mechanisms100, 101. Successful MLV proviral DNA integration into the 
target genome was only observed in dividing cells, whereas HIV-1 infection was observed in 
dividing and also non dividing cells. Possibly the large intracellular complexes of MLV can 
not be transported actively to the nucleus, so they gain only access to the host chromosome 
after breakdown of the nuclear membrane in mitosis. However, up to now it can not be 
excluded that in MLV nuclear transport other mechanisms might be involved as well99. After 
nuclear import, viral DNA is inserted into the host cell genome, a process termed integration. 
Historically, integration events of retroviruses were believed to be randomly distributed 
throughout the genome. However, gene therapy studies with MLV derived vectors showed 
malignant transformations after two independent insertions near the same growth-promoting 
gene lmo278. For MLV and MLV-based vectors a preference of integration events have been 
observed in the vicinity of transcription start regions 102, of CpG islands and of DNaseI-
hypersensitive sites. Different integration patterns were found for HIV-1 with HIV-1 preferably 
integrating into the coding sequences103.  
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Retroviruses as gene delivery systems 
An ideal GT vector to cure a genetic defect within hematopoiesis should integrate into the 
host genome of longterm repopulating cells. The integration should result in transgene 
expression for the entire life span of the cell and its progeny without causing severe side 
effects. For gene transfer into HSC retroviral vectors are attractive tools. Historically, 
retroviral vectors were the first viral system tested in a gene marking study in 1989 and 
applied in the first clinical GT trial in 1990104. They lead to stable longterm integration into the 
HSC genome. They are “safe” vector systems since viral genes responsible for spreading of 
viral infections can be eliminated. They integrate at predictable copy number per cell. They 
can transfer about 7 to 9 kb of foreign DNA which is sufficient for most therapeutic genes.  
The most frequently used vector system for HSC transduction in clinical trials is derived from 
the MLV genome. The retroviral vectors used in GT applications are replication defective. In 
these vectors the genetic information elementary for virus production in infected cells was 
deleted. Instead, the coding gene regions (gag, pol, env) which are necessary for generation 
of retroviral particles are provided in trans during virus production. Packaging cell lines have 
been produced by stably integration of plasmids encoding the gag/pol and/or env open 
reading frames (ORF) to provide corresponding gene products in trans during virus 
production. Nowadays, there are several different packaging cell line systems available 
(reviewed by105). By changing virus envelope proteins (encoded by the env gene) the target 
cell specificity of the viral vector can be modified. For clinical HSC transduction, vectors 
pseudotyped with amphotropic MLV- or gibbon ape leukemia virus (GALV) envelope have 
been used.  
In the last 15 years much progress has been achieved in the development of viral vectors 
derived from lentivirus (HIV-1). In comparison to γ-retroviral vectors, lentiviruses have the 
advantage that they are able to integrate into a variety of nondividing cells100. This would be 
particular attractive for HSC transduction since true stemcells are predominantly dormant 
(reviewed by106). However, the transduction of non-proliferating CD34+ cells from X-CGD 
patients by HIV-1 derived lentiviral vector resulted only in low transduction rates, whereas 
highest transduction rates could be observed after stimulation of cell proliferation by multiple 
cytokines107. Another very important issue for lentiviral vectors is the biosafety with respect to 
the pathogenicity of the parental virus. The wild type HIV virus encodes the vif, vpr, vpu and 
the nef ORFs. Their gene products are dispensable for virus production but are involved in 
HIV pathogenesis. In third generation lentiviral vectors these ORFs were deleted, which 
added to the safety of these vectors108-110. The development of so called self-inactivating 
(SIN) vectors has further improved the safety of MLV and HIV-1 based vectors111. The strong 
enhancers in the viral LTR of non-SIN retroviral vectors have a high potential to transactivate 
genes adjacent to the integration site. SIN vectors contain a deletion of 299 base pairs in the 
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3’ LTR including the promoter and enhancer sequences. Upon reverse transcription into 
dsDNA this deletion is copied to the 5’ LTR which results in transcriptional inactive proviral 
LTRs in the host cell genome. Desired transgene expression has to be driven by an 
additional internal promoter. Cell culture assays76 and in vivo assays112 revealed that a SIN 
vector containing strong internal enhancer/promoter showed significantly lower frequency of 
transformation by insertional mutagenesis than their LTR-driven counterparts113. A further 
reduction in transactivation activity was achieved by replacing the strong viral internal 
promoter/enhancer against a weaker cellular promoter114. In SIN vectors, the use of a tissue-
specific promoter allows to restrict the transgene expression to a certain cell population and 
limits transactivation to these cells. The risk of a single transactivation event to add to 
malignant transformation is more pronounced in stem- and progenitorcells than in terminally 
differentiated cells. In the French X-SCID trial lmo2 transactivation contributed to the 
transformation of T lymphocyte precursors78. Hence, the risk of leukomogenesis can be 
reduced significantly by restricting the promoter activity to terminally differentiated cells. 
Indeed, recently two internal cellular promoters (elongation factor-1 alpha (EF1α) and 
phoshoglycerate kinase) cloned in SIN vectors greatly decreased the risk of insertional 
transformation in cell culture systems. Even using multiple copies of the of EF1 α SIN per cell 
did not activate the crucial cellular proto-oncogene evi1114. On the other hand, the use of a 
weak cellular promoter can result in low transgen-expression115. Further improvements can 
be achieved at the post-transcriptional level. The nuclear export of RNA is known to be a rate 
limiting step116. For example, the introduction of an additional element, the so called 
woodchuck hepatitis virus post transcriptional regulatory element (WPRE) enhanced 
retroviral vector titer and expression117. WPRE facilitates nucleocytoplasmic transport of 
RNA118. Taken together, these studies underline the great impact of vector design on 
genotoxicity. 
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Foot-and-mouth disease virus 2A co-expression 
technology 
Picornaviruses, such as poliovirus and foot-and-mouth disease virus (FMDV) encode all their 
proteins within one single ORF. Individual virus proteins are derived from the polyprotein 
precursor by (auto)proteolytic processing. In the case of the FMDV and some other 
picornaviruses, the oligopeptide 2A (approx. 20 amino acid) plays a major role in polyprotein 
processing (reviewed by119). It represents a autonomous element capable of mediating 
„cleavage“ at its own C terminus together with the N-terminal residue of protein 2B (a 
conserved proline residue)56. The 2A region is not a proteinase; rather it is thought to 
mediate a ribosome skipping, a novel type of cotranslational, intraribosomal cleavage120. The 
majority of 2A and 2A-like peptides seem to form an amphipathic helix whereas the amino 
acids next to the „cleavage“ site form a tight turn121. This conformation of 2A places strain on 
the peptidyltransferase center of the ribosome and prohibits a nucleophilic attack by the 
incoming (prolyl)-tRNA amide nitrogen that normally creates the new peptide bond. A part of 
the ribosome then cease the translation process, while the other part of the ribosome 
continues the translation process and thereby effectively initiates a second polypeptide chain 
by the prolyl-tRNA to produce the downstream part as a discrete protein121, 122.  
The 2A methodology is an attractive tool for in vivo co-expression, because it only needs 
eukaryotic ribosomes to be active56. Multiple proteins can be co-expressed from a single 
mRNA by fusing multiple ORFs with intervening 2A sequences into a single, long ORF. The 
resulting single polyprotein self-processes into multiple products.  
In several studies, proteins with a signal sequence for post-translational targeting have been 
linked by the 2A polypeptide. In these constructs 2A mediated cleavage did not interfere with 
the natural localization to the nucleus, chloroplast, mitochondria, membranes or cytosolic 
tubules (reviewed by119).  
Felipe et al120 presented a model of co-translational cleavage in which one protein chain is 
directed into the endoplasmic reticulum (ER) and the other protein is synthesized in the 
cytosol (figure 8). The N-terminal portion of the cleaved polyprotein contains an ER signal 
sequence. The nascent peptide chain passes across the ER membrane. The synthesis of the 
N-terminal protein into the lumen of the ER is terminated by the 2A cleavage activity. The 
remaining C-terminal part of the polyprotein is translated irrespective of the signal sequence 
of the N-terminal part. Depending on whether or not an additional signal sequence is present, 
the translocon either re-opens to allow passage into ER or remains closed, resulting in the 
cytosolic localization or in the synthesis into the ER of the second C-terminal part of the 
original polyprotein.  
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Figure 8 Co-translational translocation and intraribosomal nascent chain cleavage by 2A (see text for details; taken from120). 
 
An alternative approach would be the use of internal ribosome entry sequences (IRESes). 
IRES sequences are able to direct ribosomes to initiate the translation of a second ORF at 
internal sites within the mRNA. Unfortunately, the Cap-initiated translation and IRES-initiated 
translation show different efficiencies. IRES-mediated translation is reported to result in a 
much lower expression level than the Cap-initiated counterpart. At limiting multiplicity of 
infection (MOI), expression in a bicistronic vector based on 2A was approx. 4 times greater 
than that of an IRES based vector123. Furthermore, problems can arise from competition 
between different IRESes124. Compared to IRES, the 2A methodology offers several 
advantages. In viral vectors the packaging capacity is limiting125. The 2A sequence (66nt) is 
much shorter than the IRES (~500nt). Most important, the mechanism of the 2A-mediated 
co-expression dictates the synthesis of two encoded proteins in a molar ratio of 1:1.  
2A functions in all eukaryontic systems, but not in prokaryotic systems122, and has already 
been applied to a broad range of biotechnical applications (reviewed by119). GT vectors 
incorporating 2A have been designed to deliver suicide genes126, to express transgenes in 
oncolytic adenoviruses127 and to quantify the expression levels of a nuclear homeoboxgene 
HoxB4 in hematopoietic stem- and precursor cells by coexpressing a cytoplasmic reporter 
gene, such as the enhanced green fluorescent protein (GFP)128.  
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Scope of the thesis  
CGD comprises a group of primary immunodeficiencies characterized by the failure of 
respiratory burst and thereby an impaired antimicrobial activity of phagocytes. 60% of all 
CGD patients suffer from mutations in the X-linked cybb gene, followed by 30% with a 
mutation in the ncf1 gene encoding p47phox 1, 13. First clinical success could be achieved in a 
recent (γ)-retroviral X-CGD gene therapy (GT) study4. This therapy represents a therapy 
complementary to BMT, which is associated with unacceptable high rates of morbidity, 
mortality and graft failure, except in very selected cases if a HLA-identical donor is 
available129, 130. However, retroviral GTs for X-CGD and ADA-SCID78 were accompanied with 
clonal dominance or leucemic progression as long-term effects of transactivation events.  
One option to minimize the risks for transactivation in CGD GT is the use of γ-retroviral SIN 
vectors111, 131, in which the viral promoter/enhancer elements are inactivated upon 
integration. The transgene expression is driven by an internal tissue-specific promoter 
element which ideally lacks enhancer activity and restricts transgene expression to terminally 
differentiated granulocytes/monocytes.  
For the p47phox-deficient form of CGD, BMT is the only therapy available at present. 
Therefore, the intended project aims to develop of a safer γ-retroviral SIN vector for gene 
replacement therapy to correct the p47phox CGD phenotype.  
  
Three major aims were formulated:  
 
First: To develop a SIN vector for p47phox CGD gene therapy we conducted two rounds of 
screening to find a potent myelospecific promoter which induces p47phox transgene 
expression upon granulocytic differentiation (chapter 1).  
 
Second: The best promoter candidate was tested in an in vivo GT in p47phox -/- mice to 
confirm its myelospecificity in vivo. In this in vivo experiment the myelospecificity of the 
p47phox transgene expression was compared to a GT conducted with a control vector 
containing the strong constitutive SFFV promoter (chapter 2).  
 
Third: The detection of p47phox expression is a mandatory requirement for GT monitoring. 
Intracellular immunostaining of the cytoplasmic p47phox transgene product interferes, 
however, with the analysis of respiratory burst activity. To overcome this limitation we 
developed a new reporter system for measuring cytoplasmic p47phox by co-expression of a 
cellular surface marker in a molar ratio of 1:1 (chapter 3).  
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 Chapter 1: 
New myelospecific self-inactivating gammaretroviral 
vectors for gene therapy of p47phox - deficient form of 
chronic granulomatous disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
written as manuscript for publication 
 
Contributions: All experiments were conducted by Vital Wohlgensinger in Zürich. Vital 
Wohlgensinger and Ulrich Siler analyzed the results. All figures in this chapter were designed 
by Vital Wohlgensinger. Ulrich Siler designed the research.  
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Abstract  
First clinical success in retroviral gene therapy (GT) could be achieved for X-linked chronic 
granulomatous disease (X-CGD), severe combined immunodificiency (X-SCID) and 
adenosine deaminase severe combined immunodificiency (ADA-SCID), but were 
accompanied with clonal dominance or leukemic progression as long term effects of 
transactivation events. To develop a GT vector for the p47phox-deficient form of chronic 
granulomatous disease (CGD) we therefore cloned various myelospecific promoter 
candidates into gamma (γ)-retroviral self-inactivating (SIN) vectors driving p47phox expression. 
The constructs were screened for myelospecific expression and functional reconstitution of 
the NADPH oxidase activity in transduced murine p47phox -/- hematopoietic stem cells (HSC) 
upon propagation to granulocytes in cell culture. By this screen we have identified a new, 
potent myelospecific promoter, microRNA-223 (miRNA-223), which results in p47phox 
expression exclusively in granulocytes. Furthermore, miRNA-223 controlled p47phox 
expression resulted in functional reconstitution of the NADPH-oxidase in cell culture. 
 
Introduction  
CGD results from an impaired respiratory burst activity caused by an inactive phagocyte 
NADPH oxidase complex1. This enzyme complex consists of two membrane spanning 
subunits (gp91phox and p22phox) plus three cytosolic components (p47phox, p67phox and p40phox). 
Approximately 60% of all CGD cases were estimated to result from mutations in the X-linked 
cybb-gene (X-CGD) encoding gp91phox followed by additional 30% caused by mutations in 
the ncf1-gene encoding p47phox 2. Unfortunately, hematopoietic stem cell transplantation 
(HSCT) for CGD has been associated with unacceptably high rates of morbidity, mortality 
and graft failure, except in very selected cases when a human leukocyte antigen (HLA) -
identical donor is available3, 4. A complementary therapeutic approach for CGD patients is the 
genetic correction of autologous HSCs. CGD could be successfully corrected in animal 
models by GT5, 6. Furthermore, a recent GT trial aimed to correct X-CGD has temporarily 
proved clinically benefit to the patients7. However, oncogene transactivation by viral long 
terminal repeat (LTR) sequences resulted in clonal dominance or leukemic progression7 8. 
These adverse events highlighted the risks associated with integrating viruses as vectors for 
gene delivery9. To minimize the risks for transactivation, we have developed a series of SIN 
γ-retroviral vectors for p47phox GT. SIN vectors contain a deletion within the U3 region of the 
viral 3’ LTR which results in the inactivation of the viral promoter/enhancer elements upon 
reverse transcription10. Transgene expression is driven by an internal tissue-specific 
promoter element which ideally lacks enhancer activity. E. g. a myelospecific promoter 
restricts the transgene-expression to terminally differentiated granulocytes/monocytes and 
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thereby prevents transactivation events in HSC. In the literature several promoter sequences 
have been described which resulted in myelospecific gene expression. Table 1 summarizes 
some myelospecific promoter elements which were tested in our study.  
 
Myeloid promoter 
Transcription 
factor (TF) binding 
sites 
Description Size, bp 
human p47phox promoter 
PU.111,ISRE12, 
HBP113, Sp114, 
PEA311, PEBP211, 
Ets-111 
Regulates myelospecific human p47phox expression: p47phox 
expression is mainly found in myeloid cells, e.g. 
neutrophils, monocytes, but also in B-cells.  
Only 58bp of the proximal p47phox sequence including PU.1 
TF binding site were reported to be sufficient to direct 
significant reporter gene activity in myeloid cells15. 
305011 
human p40phox promoter PU.116 
Restricts human p40phox expression to myeloid lineage; 
proximal 106 base pairs of 5’-flanking region of the human 
p40phox gene exhibited maximum myeloid promoter 
activity16.  
10616 
c-fes promoter 
SP1, PU.1 and 
unknown new TF17 
Regulates expression of tyrosine kinase being essential in 
monocytic and neutrophilic development17, 18 
504* 
mrp-8 
IRF-1, CDP/NF-y, 
CBP, GT1, PU.119 
Regulates expression of myeloid calcium binding protein 
MRP-8 found in granulocytes, monocytes and 
macrophages20, which is involved in regulation of NADPH-
oxidase.  
1584* 
sp-107 
PU.1, SP1 sites, 
c/EBPα, AML21 
Synthetic promoter element generated by random ligation 
of myeloid/macrophage cis elements21.  
265* 
microRNA-223 
 (miRNA-223) 
Not yet published; 
e.g. PU.1, ISRE, 
Evi1 
 (predicted by 
MatInspector 
(Genomatix, 
software)). 
Involved in regulation of granulocyte differentiation and 
linked miR-223 RNA showed a highly lineage-specific 
expression pattern for miR-22322.  
783* 
 
Table 1 Short description of myelospecific promoters used in this study. Abbreviations: purine rich box-1 (PU.1); interferon-
stimulated responsive elements (ISRE); high mobility group (HMG)-box containing protein 1 (HBP1); polyoma virus enhancer 
activator 3 (PEA3); phosphatidylethanolamine binding protein 2 (PEBP2); interferon regulatory factor 1 (IRF-1); CCAAT-box 
binding TF (NF-Y CDP/NF-y CBP GT1); TF erythroblastosis virus E26 oncogene homologue 1 (Ets-1); CREB-binding protein 
(CBP); C/AAT enhancer binding protein (c/EBPα);  acute myeloid leukemia-1 (AML); ecotropic viral integration site-1 (Evi1); 
*refers to size of the specified promoter-element used in this study.  
 
Gene expression relies not solely on gene-proximal elements such as promoters, enhancers 
and silencers. Long-range interactions of various cis regulatory elements and chromatin 
modifications can also influence gene expression. This was shown e.g. for the locus control 
regions (LCR) which have the ability to enhance the expression of linked genes in a tissue-
specific and copy number-dependent manner at ectopic chromatin sites23. For the cfes gene, 
a LCR was identified which in combination with the myelospecific cfes promoter directed 
transgene expression in a myeloid-restricted manner24.  
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To develop a SIN vector for p47phox CGD GT we performed two rounds of screening to find a 
potent internal promoter. In the first screen, different myelospecific promoters driving GFP 
expression were tested. Potent candidates were then cloned into a (γ)-retroviral SIN vector 5’ 
to the p47phox open reading frame (ORF). The constructs were screened for ex vivo 
myelospecific expression of p47phox and functional reconstitution in transduced murine 
p47phox -/- HSCs upon propagation to granulocytes in cell culture. These two screens 
revealed a new potent promoter, miRNA-223, which restricts p47phox expression exclusively 
to granulocytes.  
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Results 
First screen for myelospecificity in PLB-985 cells 
In a first screen a panel of (mainly human p47phox-promotor based) lentiviral promoter 
constructs was tested for myelospecific expression of green fluorescent protein (GFP) as a 
marker gene (figure 1). We tested these constructs in premyeloid PLB-985 cells (DSMZ no.: 
ACC 139) as these cells can be differentiated to neutrophils in vitro.  
 
Figure 1 Schematic diagram of the vectors used in the first screen. The structures of the cloned lentiviral vector plasmids are 
shown. 
SEW SFFVU3 GFP is a lentiviral SIN vector (majority of U3 deleted in the 3’-LTR with an internal SFFV promoter) driving GFP-
expression and used as constitutive active positive control. SEW GFP LCR is the negative control without promoter.  
SFFV denotes the enhancer and promoter elements derived from the LTR of the spleen focus forming virus. Ψ, packaging 
signal; LTR, long terminal repeat; SA, splice acceptor site; SD, splice donor site; RRE, rev-responsive element; GA, truncated 
gag region; WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element; cfes-LCR, cfes-locus control regions;  
 
For each promoter construct, virus supernatant was produced by calcium phosphate 
mediated cotransfection of human embryonic kidney (HEK) 293T cells (ACC 305) with three 
plasmids: pCMV∆8.91 (encoding the lentiviral Gag/Pol), pMDG2.G (encoding the VSV 
envelope (vesicular stomatitis virus G glycoprotein)) and with the gene transfer vector as 
shown above (figure 1).  
To quantify the myelospecificity of our promoter constructs, myeloid cell line PLB-985 cells 
were transduced at molarity of infectivity (MOI) equal to 1 according to prior titration. 
Thereafter, half of each transduced cell population was propagated to terminally 
differentiated neutrophils by liquid cell culture in presence of 0.5% dimethylformamide (DMF) 
for 6 days. The other half of the transduced cells was cultured further in parallel. Both 
transduced cell populations, the undifferentiated PLB-985 cells and the CD11b+ PLB-985 
cells, were then analyzed for GFP expression by flow cytometry.  
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The absolute GFP signal intensity in differentiated PLB-985 neutrophils (CD11b+) (figure 2b) 
as well as the ratio between the means of differentiated and undifferentiated PLB-985 cells 
(figure 2a) were highest for the synthetic promoter construct “sp107” (with nine PU.1 
transcription factor binding sites) followed by the mixed promoter “p40/48“ (with three PU.1 
sites) indicating myelospecificity and inducibility of these two promoters.  
 
Figure 2 Screen of myelospecific GFP expressing lentiviral promoter constructs in premyeloid PLB-985 cell line. PLB-985 cells 
were lentivirally transduced. PLB-985 cells were differentiated in liquid cell culture in the presence of 0.5% DMF. The expression 
of GFP was monitored by FACS analysis after 6 days in undifferentiated and in differentiated CD11b+ PLB-985 cells.  
(a) Ratio of GFP mean fluorescence intensity (MFI) between CD11b+ (differentiated) and undifferentiated PLB-985 cells 
transduced with indicated lentiviral SIN vectors. Means and standard deviations of two independent experiments are shown. To 
avoid multicopy integrations, transduction rates were kept at MOI=1 according to prior performed titration. 
 (b) Absolute mean GFP fluorescence intensity (MFI) within the GFP-positive population of differentiated CD11b+ PLB-985 cells. 
Means and standard deviations of two independent experiments are shown. To avoid multicopy integrations, transduction rates 
were kept at MOI=1 according to prior performed titration.  
                                                                                                                                                                                             
Generation of gammaretroviral SIN vector constructs 
This first screen allowed us to pre-select the most promising candidates among the tested 
promoter constructs according to their myelospecific GFP expression in the premyeloid PLB-
985 cell-line25. In the next step, we cloned the p47phox transgene (M25665, codon optimized) 
into a γ -retroviral pSERS11M8delN91s SIN vector (kind gift of M. Grez, Frankfurt, Germany) 
to express p47phox in hematopoietic cells. This vector contains an optimized backbone 
architecture including deletion of enhancer and TATA box (SIN configuration) and an internal 
myelospecific mrp8 promotor20. Based on this construct we generated retroviral constructs 
containing the p47phox transgene under control of different internal myelospecific promoters: 
sp-107, cfes, p40/48, miRNA-223 (miR-223) and for comparison the constitutively active 
SFFV promoter (figure 3).  
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Figure 3 Schematic diagram of cloned gamma (γ) -retroviral SIN vectors with p47phox as transgene (plasmid configuration) under 
control of different internal myelospecific promoters. The SFFV promoter construct was used as constitutive active control.  
The following items are indicated: The SIN configuration is indicated by partial deletion of the U3 (∆) in the 3’ LTR and the 
presence of an internal promoter. SD, splice donor site; Ψ, packaging signal; LTR, long terminal repeat. WPRE, Woodchuck 
hepatitis virus posttranscriptional regulatory element; U3, R, U5 denote LTR subunits.  
 
Screen of myelospecific promoter constructs in primary murine 
p47phox -/- lineage negative bone marrow cells 
To select the most promising promoter candidate we transduced murine p47phox -/- lineage 
negative (Lin-) bone marrow (BM) cells with the generated γ -retroviral vectors expressing 
p47phox under control of different myelospecific promoters at low MOI. 48h after transduction, 
the cell populations were split in two. One half was analyzed for p47phox transgene 
expression in undifferentiated ScaI+ cells. The other half was ex vivo differentiated to Ly6G 
(GR1)+ granulocytes in liquid cell culture for at least 10 days followed by p47phox flow 
cytometry analysis (FACS). In ScaI+ undifferentiated cells the transduction efficiency was 
below 25% confirming that the majority of the transduced cells contained statistically just one 
integration per cell26. Among all tested myelospecific constructs the miR-223 promoter 
showed the highest p47phox mean fluorescence intensity (MFI) within the Ly6G (Gr1)+ 
population, followed by the p40/48 promoter and the cfes promoter constructs (figure 4c). 
Analysis of the p47phox MFI ratio between differentiated (Ly6G+/p47phox+) and undifferentiated 
(ScaI+/p47phox+) cells lead to the same conclusion. Among all promoter constructs miR-223 
promoter construct showed most myelospecific p47phox MFI expression compared to the 
constitutive active SFFV control (figure 4b).  
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Figure 4 Screen of myelospecific p47phox expressing promoter constructs in primary murine p47phox-/- BM cells. Lin- BM cells  of 
p47phox -/- mice were retrovirally transduced. The expression of the p47phox transgene was monitored by FACS analysis after 4 
days in ScaI+ BM cells and in Ly6G+ (Gr1+) cells upon differentiation in liquid cell culture.  
(a) Representative histograms of murine Lin- BM cells transduced with SFFV-p47phox or miR-223-p47phox γ-retroviral SIN vectors 
at low (MOI) in undifferentiated ScaI+ murine bone marrow (BM) cells and in differentiated Ly6G+ (GR1+) positive cells. To 
avoid multicopy integrations, transduction rates were MOI=1; γ-retroviral titers were predetermined in the murine pro B cell line 
BA/F3 (ACC 300) by real-time Q-PCR. MFI of the p47phox positive cells was measured by performing intracellular staining of 
p47phox followed by flow cytometry analysis.  
(b) Induction of p47phox transgene expression upon differentiation: Ratio of MFI in ScaI+ BM cells divided by MFI in GR1+ cells. 
MFI ratios and standard deviations of at least three independent experiments are shown.  
(c) Absolute p47phox expression (FACS MFI) in undifferentiated ScaI+ BM cells and in differentiated GR1+ cells. MFIs and 
standard deviations of at least three independent experiments are shown.  
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Functional reconstitution of NADPH oxidase activity in transduced 
and ex vivo differentiated Ly6G (Gr1)+ murine neutrophils 
The production of reactive oxygen species (ROS) in granulocytes can be monitored by the 
dihydrorhodamine-123 (DHR) assay. In this assay, the oxidation of non-fluorescent DHR 123 
to fluorescent rhodamine by ROS allows the detection of ROS producing cells by FACS 
analysis. Therefore we applied this methodology to analyze whether the vector constructs 
are able to restore the NADPH oxidase activity in Ly6G/Ly6C+ granulocytes. Upon phorbol 
12-myristate 13-acetate (PMA) stimulation, the shift in DHR signal (figure 5a) demonstrated 
that transduction by the constitutive control (SFFV) or the myelospecific promoters (cfes, 
p40/48 and miRNA-223) constructs resulted in the restoration of NADPH oxidase activity. 
The percentage of 5 to 21% DHR+ cells reflects the expected transduction rate after 
transduction with MOI=1. Only a small fraction (about 0.5%) of DHR+ cells could be 
observed in case of the sp107 and mrp8 promoter constructs (figure 2b) which resulted from 
significant lower virus titers. Analysis of the MFI within the DHR+ cell population showed 
similar shift between the constitutive control and the indicated myelospecific promoter 
constructs (figure 2c). Taken together, we have shown in our screen that the miRNA-223 
promoter construct showed the best induction of p47phox expression upon neutrophilic 
differentiation among all other promoter candidates and that the miRNA-223 promoter 
construct restored the NADPH oxidase activity in murine p47phox -/- cells.  
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Figure 5 γ-retroviral reconstitution of the NADPH oxidase activity. Murine Lin- BM cells from p47phox -/- mice were γ-retrovirally 
transduced and differentiated to Ly6G (Gr1)+ granulocytes. The reconstitution of NADPH oxidase activity upon PMA stimulation 
was analyzed by a DHR 123 oxidation assay within the Gr1+ cell population.  
(a) Representative examples of FACS based DHR 123 oxidation analysis in Gr1+ cells. % and MFI of DHR positive population 
within Ly6G (Gr1)+ murine neutrophils are indicated. 
(b) Percentage (%) of DHR+ cells within Ly6G (Gr1)+ murine neutrophils. % and standard deviations of three independent 
experiments are shown.  
(c) MFI of the DHR+ population in stimulated and unstimulated granulocytes. MFIs and standard deviations of three 
independent experiments are shown.  
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Discussion 
To develop a GT vector aimed to correct the p47phox-deficient form of CGD we screened 
several promoter sequences for their potency of driving transgene expression in myeloid 
cells, especially in neutrophils. The rationale of this approach is based on the fact that the 
observed clonal dominance and malignant transformations resulted from the transactivation 
of oncogenes adjacent to the viral integration site in stem- and progenitorcells. Therefore, 
restricting the expression of therapeutic transgene to short-lived neutrophils will decrease the 
likelihood of side effects like malignant transformation.  
We first screened our promoter candidates in PLB-985 cells. The differentiation status of the 
pre-myeloid cell line PLB-985 is somewhere in the middle on the differentiation pathway 
between HSCs and neutrophils. The cells can be differentiated in vitro either to granulocytes 
in the presence of DMF or dimethylsulfoxide (DMSO), or to monocytes in the presence of 
PMA25. The myelospecificity of our promoters was estimated according to the increase in 
promoter candidates’ driven GFP expression upon differentiation to granulocytes. 
Surprisingly, only two constructs showed induction of GFP expression upon myelospecific 
differentiation. These were namely the synthetic promoter construct “sp107” and the mixed 
“p40/48” promoter consisting of human p47phox and p40phox promoter sequences. The other 
constructs mainly based on the human p47phox promoter. It is not clear, why these constructs 
did not show myelospecific expression of GFP. Possibly, these p47phox promoter constructs 
are already activated to a certain extent on the differentiation status of undifferentiated PLB-
985 cells. Hence, differentiation would result in only a weak activation of these promoters in 
the PLB system. Among the p47phox promoter constructs the mixed promoter “p40/48” 
showed the strongest increase in GFP expression upon myelospecific differentiation. The 
“p40/48” promoter consists of p47phox and of p40phox sequences and possesses all together 
three PU.1 sites. The synthetic promoter sp107 contains nine PU.1 sites and showed an 
even stronger myelospecific GFP expression. These results are in line with the reported role 
of TF PU.1 in myelospecific expression11, 15, 16, 27. However, the use of the sp107 vector with 
nine repetitive PU.1 sites needs to be analyzed carefully. It is known that repetitive 
sequences within retroviral genomes are unstable and are deleted frequently upon reverse 
transcription; a process called reverse transcriptase (RT) template switching28, 29. However, 
none of the other cloned TF binding sites contributed as strong as the PU.1 TF site to 
myelospecific expression. They rather seem to repress myelospecific GFP expression as 
seen for the construct “p47_3PU.1”.  
In summary, this first screen in PLB-985 cells revealed a moderate myelospecific property for 
the cfes promoter and significant myelospecific transgene induction by the “p40/48” and the 
“sp107” promoter. 
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We then switched to γ-retroviral vectors containing the p47phox transgene instead of GFP 
reporter gene, since γ-retroviral vectors have been used in the latest temporarily successful 
clinical GT X-CGD trial7.  
For detection of the cytoplasmic p47phox transgene product we established the intracellular 
staining (ICS) with an anti-p47phox antibody followed by flow cytometry analyses. The 
detection of p47phox by ICS is new as in previous p47phox studies the expression was mainly 
detected by western blot analyses of crude cell extracts30 or indirectly by performing 
functional NADPH oxidase activity assays5. Furthermore, we increased the γ-retroviral vector 
titers by two logs and we significantly reduced their toxicity. This was done by (I) optimizing 
the plasmid concentration utilized for virus production (II) shifting from the calcium phosphate 
method to a transfection reagent and (III) concentrating the virus supernatant. 
The 2nd screen was performed in primary murine p47phox -/- Lin- BM cells; the primary target 
organ in later clinical use. In addition to the three promoters favoured by the first screen, we 
tested the “mrp8” promoter and the “miRNA-223” promoter (kind gift of our collaboration 
partner M. Grez). Again, myelospecificity was estimated by the ratio between the expression 
in Lin- BM cells and in terminally differentiated Gr1+ granulocytes.  
In case of the synthetic promoter “sp107” the myelospecific expression seen in the GFP 
PLB-985 screen could not be confirmed in the 2nd screen. In the case of the “mrp8” 
promoter construct it was difficult to obtain high titers. This could be due to the promoter size 
(around 1.5 kb). Furthermore, the “mrp8” promoter contains splice sites which might result in 
deletions during retroviral life cycle.  
By far the strongest induction of p47phox expression was observed for the “miRNA-223” 
promoter. Considering the absolute MFI values of p47phox expression, a relatively high signal 
in undifferentiated ScaI+ cells of all constructs was observed. This was unexpected for 
myelospecific promoters as they should not be active in the progenitor/stem cells. Possibly, 
the high MFI of p47phox expression measured in undifferentiated ScaI+ cells is due to the 
presence of unintegrated circular DNA31. In terminally differentiated granulocytes these 
unintegrated circular viral DNA got lost due to dilution as the cells proliferate upon 
differentiation. We determined the MOI in terminally differentiated granulocytes. This MOI 
just refers to the integrated viral DNA. The actual MOI which results initially in unintegrated 
circular DNA plus integrated DNA might be higher. Therefore, we can’t exclude the possibility 
that we compared in our assay multiple copies of unintegrated circular DNA in 
progenitor/stem cells with a single copy situation in granulocytes. This challenge is hard to 
circumvent as later analysis of undifferentiated ScaI+ cells bears the risk of loosing 
undifferentiated cells due to continuous differentiation. If this is true, minor myelospecific 
expression effects can not be detected by this screen. This would possibly explain the 
absence of myelospecificity observed in other myelospecific promoter constructs.  
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Finally, we demonstrated in p47phox -/- cells that the transgenic expression of p47phox under 
control of “cfes”, “p40/48” or the “miRNA-223” promoter resulted in reconstitution the NADPH 
oxidase function. For all promoter constructs the shift in the FACS signal within the DHR test 
was comparable to the shift observed for the strong and constitutively active SFFV promoter. 
Already 5% of functional granulocytes are sufficient to protect a patient against infections32-34.  
Therefore GT with myelospecific SIN vectors as they were used in this study could lead to 
sufficient number of corrected cells with sufficient NADPH oxidase activity. The presented 
combination of a γ-retroviral SIN vector with a strictly myelospecific internal promoter, e. g. 
miRNA-223, represents a major safety improvement as it minimizes the risk of malignant 
transformations in stem- and progenitor cells as longterm effect of insertional mutagenesis. 
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Materials and methods 
Cell culture 
Non-adherent growing PLB-985 (ACC 139) cells were grown in RPMI 1640 (PAA 
Laborotories), 2% Antibiotic/Antimycotic (PAA Laborotories). PLB-985 cells were 
differentiated to neutrophils in RPMI 1640 (PAA Laborotories), 0.5% DMF (Sigma), 2.5% 
foetal bovine serum (FBS) (PAA Laborotories), 2% Antibiotic/Antimycotic (PAA Laborotories) 
for 6 days. Murine pro B cell line BA/F3 (ACC 300) were cultured as were PLB-985 cells 
supplemented with 10ng/ml mIL-3 (Peprotech). 
Murine p47phox -/- Lin- BM cells were harvested from femora and tibiae of p47phox -/- mice 
(B6(Cg)-Ncf1m1J/J) (Jackson Laboratory) and enriched by the “Lineage Cell Depletion Kit” 
(Miltenyi Biotec). Isolated BM cells were cultured in StemSpan H3000 medium (StemCell 
Technologies) supplemented with 50 ng/ml murine stem cell factor (mSCF) (Peprotech), 100 
ng/ml human Flt-3 ligand (Peprotech), 100 ng/ml human interleukin-11 (IL-11) (Peprotech), 
20 ng/ml murine IL-3 (Peprotech), 1% penicillin/streptomycin (GIBCO), 2 mM glutamine 
(GIBCO)35 and 2% FBS (Hyclone Thermoscientific).  
For differentiation of murine Lin- BM cells to granulocytes see section “Transduction of 
murine p47phox -/- Lin- BM cells”.  
 
Cloning of lentiviral vectors and production of infectious particles 
For SIN lentiviral vectors, the backbone was described recently36. The internal promoter 
fragment (EcoRI/BamHI) was exchanged by PCR products of different myelospecific 
promoter sequences as illustrated above (figure 1). cfes-LCR was cloned into lentiviral vector 
into its MluI site. Infectious particles were transiently generated by HEK 293T cells (ACC 
305) by transfecting a 70-80% confluent cell layer using calcium phosphate methodology. In 
a 10 cm petridish 6.5µg pCMV∆8.91 (encoding lentiviral GagPol), 3.5µg pMDG2.G (encoding 
VSV envelope) and 10µg gene transfer vector were co-transfected into HEK 293T packaging 
cells. Cells were incubated for 6h in the presence of the DNA/calcium phosphate precipitate 
and 100µM Chloroquin (Sigma), washed and cultured in fresh medium. Infectious particles 
containing cell culture supernatants were collected 24h and 48h after transfection, sterile 
filtered (Millipore) and stored immediately at -80°C. For titration, serial dilutions of viral 
supernatants were utilized to infect PLB-985 cells (ACC 139) in the presence of protamine 
sulfate (8µg/ml, Sigma). Freshly thawed virus supernatant was spinoculated onto the cells 
(90 min, 2500 RPM, at 32°C). 3 days later the percentage of green fluorescent protein (GFP) 
expressing cells was determined by flow cytometry (FACS Calibur, Becton-Dickinson (BD) 
Biosciences). Transduction efficiencies above 20 % result in a significant portion of cells with 
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more than one integration26. Therefore, we calculated the titer just from those transductions 
which resulted in a maximum of 20% GFP+ cells. For calculation we used following formula:  
 
Titer (transducing units/ml) = 
= seeded cell number x dilution factor of virus supernatant x (GFP positive cells (%)/100%).  
 
Cloning of γ-retroviral vectors and production of infectious particles  
The γ-retroviral pSERS11M8delN91s SIN vector (a derivate of the SERS11.SF.GFP.W 10, 
kindly provided by M. Grez, Georg Speyer, Frankfurt) was used as basic construct. 
pSERS11M8delN91s SIN vector contains the internal mrp8 promoter 5’ to the gp91phox 
coding reading frame (CRF). In the first step a Sal I-restriction site was inserted between the 
gp91phox CRF and the Woodchuck hepatitis virus post-transcriptional element (WPRE) by site 
directed mutagenesis (Stratagene). Then, the gp91phox CRF was substituted by human 
p47phox CRF (M25665, codon optimized by GENEART) by BamH1/SalI (New England 
Biolabs (NEB)) restriction digestion. All other promoters were cloned into this vector by 
replacing the NdeI/BamHI mrp8 promoter fragment. The constitutive active promoter 
sequence SFFV was amplified from SERS11.SF.GFP.W (kindly provided from M. Grez, 
Georg-Speyer-Haus, Institute for biomedical research, Frankfurt, Germany). The sp107 
promoter derived from “Lenti-sp107-GFP” 21 (kindly provided from Senlin Li, University of 
Texas, Department of Medicine, USA) and the miRNA-223 promoter from “223-1 gps W” 
(kindly provided from M. Grez, Georg-Speyer-Haus, Institute for biomedical research, 
Frankfurt, Germany).  
For construction, the recombinant plasmids were introduced by electroporation (Gene Pulser, 
Biorad) or heat shock into E. Coli Top-10 competent cells (Invitrogen). DNA manipulations 
were performed according to standard procedures by using commercial kits (Quiagen, 
Macherey-Nagel, Genomed). All resulting constructs were controled by restriction digestion 
followed by agarose gel electrophoresis. The cloning sites and flanking sequences of the 
resulting constructs were confirmed by DNA sequencing (ABI PRISM 3130xl Genetic 
Analyzer, Applied Biosystems (AB)).  
Ecotropic infectious particles were generated by transient transfection of Phoenix (ΦE) cells 
(ACC 3444). These cells are derived from HEK 293T cells by stably integration of a plasmid 
carrying the moloney murine like virus (MLV) gag-pol CRFs and with an ecotropic MLV env 
expressing plasmid. In a 10 cm petridish, 70-80% confluent Phoenix E cell layers were co-
transfected by 4µl TransIT-293 reagent (Mirus LCC Bio) per µg (total DNA), 10µg pUMVC 
(encoding γ-retroviral GagPol), 4µg M187 (encoding ecotropic envelope) and 40µg gene 
transfer vector. Infectious particle containing cell culture supernatants were collected 24h, 
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48h, 60h after transfection and sterile filtered (Millex Syringe Driven Filter units, 0.45 µm pore 
size (Millipore)). The supernatant was concentrated (30X) (Amicon-Ultra 15 centrifugal units, 
1500g, 18min at RT) from 15ml to an end volume of 500µl and frozen immediately in form of 
aliquots a 20µl at -80°C. For titration, serial dilutions of viral supernatants were used to infect 
the murine pro B cell line BA/F3 (ACC 300) in the presence of protamine sulfate (8µg/ml, 
Sigma). Virus supernatant was thawed and taken immediately for transduction (spinoculation 
for 90 min, 2500 RPM, at 32°C). One week after transduction DNA was extracted from the 
cell pellets by „DNeasy blood and tissue kit“ (Qiagen). The vector copy number was 
quantified by real-time quantitative PCR (q-PCR) with 50-200 ng template DNA in a reaction 
volume of 25µl. The set of primers and probes used for the analysis were as follows (table 2): 
 
detect primers/probes sequence final 
concentration, 
nM 
company 
forward primer 5’-AGAGGGAAATCGTGCGTGAC-3’ 500 Microsynth 
reverse primer 5’-CAATAGTGATGACCTGGCCGT-3’ 500 Microsynth 
actb (encoding β-
actin) 
(endogenous control) probe VIC-CACTGCCGCATCCTCTTCCTCCC-
MGB 
200 AB 
forward primer 5’-TTTCTGGGACTTTCGCTTTCC-3’ 500 Microsynth 
reverse primer 5’-AGGCGGCGATGAGTTCTG-3’ 500 Microsynth 
WPRE 
probe FAM-CCTCCCGATCGCC-MGB 200 AB 
Table 2 Primers and probes used for real-time q-PCR.  
 
We generated a standard curve by combining DNA from BA/F3 cells without and with one 
integration per cell (kindly provided from M. Grez, Georg-Speyer-Haus, Institute for 
biomedical research, Frankfurt, Germany). TaqMan reactions were carried out in triplicates in 
an ABI Prism 7700 HT Sequence Detection System (AB). Transduction of HSC and different 
cell lines (e.g. BA/F3 cells) with one and the same virus supernatant resulted in different 
transduction efficiencies. Therefore, we determined the factor between the titers related to 
BA/F3 cells and HSC. Murine Lin- BM cells and BA/F3 cells were transduced with the SFFV 
control virus supernatant and analyzed 5 days later by intracellular p47phox staining measured 
by FACS (BD). The titer in BA/F3 cells was calculated to be 1.6 fold higher compared to 
HSCs.  
 
Detection of transgene expression in individual hematopoietic cell 
populations 
In differentiated PLB-985 cells granulocytic maturation was estimated according to CD11b 
induction. Only CD11b+ cells (antibody-clone ICRF44) were analyzed for GFP expression.  
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p47phox expression was measured by performing ICS with the anti-p47phox antibody (clone 1), 
APC-labeled by BD-services. For combined staining of surface markers and intracellular 
p47phox, the cells were first blocked with mouse Fc-block (BD) (clone 2.462) for 10min at 4°C, 
incubated with the surface antibodies for 1h at 37°C and washed twice. Thereafter, p47phox 
was stained with APC anti-p47phox using the Cytofix/Cytoperm Kit (BD) according to 
manufacturer’s instructions. FITC anti-Ly-6G (clone 1A8, BD) was used to detect murine 
neutrophils and anti-Ly-6A/E ScaI (clone E13-161.7, BD) to detect murine stem- and 
progenitor cell enriched cell populations.  
 
Transduction of murine p47phox -/- Lin- BM cells 
p47phox -/- Lin- BM cells were isolated using the lineage cell depletion kit (Miltenyi). The BM 
cells were cultured for 2 to 3 days in StemSpan H3000 supplemented with cytokines (see cell 
culture section). Cell culture plates were precoated with Retronectin (TaKaRa) by incubation 
with 10 µg/cm2 at RT for 2h followed by HSA incubation for 10 min. Frozen titered γ-retroviral 
supernatants were thawed, prediluted in StemSpan H3000 and loaded onto the precoated 
plates by centrifugation (3000 RPM for 30 min at 4°C). Then, p47phox -/- Lin- BM cells were 
seeded onto virus-loaded plates and cultured for 3 to 5 days in cytokine supplemented 
StemSpan H300035.  
For later intended p47phox FACS analysis of ex vivo differentiated granulocytes, the Lin- BM 
cells were washed two days after transduction and incubated for 10-12 days in fresh stem 
cell culture medium additionally supplemented with 100ng/ml mG-CSF.  
For later intended functional analysis (DHR assay) of ex vivo differentiated granulocytes, the 
Lin- BM cells were washed twice 2-3 days after transduction to get rid off all “stem cell 
cytokines”. The cells were then incubated in RPMI, 20% FBS, 100ng/ml mG-CSF and 10 
ng/ml mIL-3 for 4 to 6 days.  
 
Analysis of respiratory burst activity  
For analyses of respiratory burst activity, the dihydrorhodamine assay (DHR) 123 was 
carried out as described7 with one modification. We combined the FACS based DHR assay 
with the analysis of cell surface markers. In the DHR 123 assay, ex vivo differentiated murine 
neutrophils (see above) were identified by prestaining with PerCP-Cy5.5 anti-Ly-6G and Ly-
6C (clone RB6-8C5, BD). Then, the cells were stimulated with 1µg/ml PMA (SIGMA) for 
15min at 37°C in presence of DHR. A shift in DHR 123 fluorescence was measured by flow 
cytometry (BD) within 30 min after stimulation.  
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 Chapter 2: 
Gene therapy of p47phox -/- deficient CGD mice using 
new myelospecific self-inactivating gammaretroviral 
vectors  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
written as manuscript for publication 
 
Contributions: All experiments were conducted by Vital Wohlgensinger in Zürich. Vital 
Wohlgensinger and Ulrich Siler analyzed the results. All figures in this chapter were designed 
by Vital Wohlgensinger. Ulrich Siler designed the research.  
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Abstract  
First clinical success in retroviral GT could be achieved for X-CGD and ADA-SCID, but were 
accompanied with clonal dominance or leukemic progression as long term effects of 
transactivation events. To develop a GT vector for the p47phox-deficient form of CGD we have 
previously screened various myelospecific promoters in gamma (γ) -retroviral self-inactivating 
(SIN) vectors driving p47phox expression. The best promoter candidate, the microRNA-223 
(miRNA-223) promoter, was utilized in an in vivo GT in p47phox -/- mice and the outcome was 
compared to the constitutive active control vector. GT with miRNA-223 vector resulted in 
clear myelospecific p47phox transgene expression and restored the function of the NADPH 
oxidase in target neutrophils in vivo. The presented combination of a γ-retroviral SIN vector 
with a strictly myelospecific promoter represents a major safety improvement in CGD GT. 
 
Introduction  
Chronic granulomatous disease (CGD) results from an impaired respiratory burst activity 
caused by an inactive phagocyte NADPH oxidase complex1. This enzyme complex consists 
of two membrane spanning subunits (gp91phox and p22phox) plus three cytosolic components 
(p47phox, p67phox and p40phox). Approximately 60% of all CGD cases were estimated to result 
from mutations in the X-linked cybb-gene encoding gp91phox followed by additional 30% 
caused by mutations in the ncf1-gene encoding p47phox 2. Unfortunately, hematopoietic stem 
cell  transplantation (HSCT) for CGD has been associated with unacceptably high rates of 
morbidity, mortality and graft failure, except in very selected cases in which a human 
leukocyte antigen (HLA) -identical donor is available3, 4. As a HLA-identical donor can only be 
found for about 50% of the patients5 a therapy for CGD complementary to HSCT is highly 
desired for the other half of the patients lacking an appropriate BM donor. CGD could be 
successfully corrected in animal models by GT6, 7. Though limited in time, clinical success 
could be shown in recent GT aimed to correct X-CGD8. However, oncogene transactivation 
by viral LTR sequences resulted in clonal dominance8 or leukemic progression9. These 
adverse events highlighted the risks associated with integrating viruses as vectors for gene 
delivery10. To minimize the risks of transactivation, we have previously developed series of 
SIN γ-retroviral vectors for p47phox GT (see chapter 1). SIN vectors contain a deletion within 
the U3 region of the viral 3’ LTR which results in inactivation of the viral promoter/enhancer 
elements upon reverse transcription11. Transgene expression is driven by an internal tissue-
specific promoter element which ideally lacks enhancer activity. E. g. a myelospecific 
promoter restricts the transgene expression to terminally differentiated 
granulocytes/monocytes and thereby prevents transactivation events in HSC.  
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In our previous screen in ex vivo transduced murine p47phox -/- hematopoietic stem cells 
(HSC), we have shown that the myelospecific microRNA-223 (miRNA-223) promoter induces 
the p47phox expression upon granulocytic differentiation (see chapter 1). In the present study 
we conducted a BM transplantation in p47phox -/- mice with ex vivo transduced (γ-SIN vector, 
miRNA-223 promoter, p47phox transgene) autologous HSC to test its feasibility in p47phox CGD 
GT. To validate the myelospecific p47phox transgene expression, the outcome was compared 
to a GT with a control vector containing the strong constitutive SFFV promoter. We show 
here that GT in p47phox -/- mice using miRNA-223 vector resulted in strictly myelospecific 
p47phox transgene expression. Furthermore, GT with our vector in p47phox -/- mice functionally 
corrected the CGD phenotype.  
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Results 
(γ) -retroviral SIN vectors for GT of the p47phox -deficient form of 
CGD  
For GT of the p47phox -deficient form of CGD we used two (γ) -retroviral SIN vectors which 
have been generated previously (see chapter 1). These vectors contain the human p47phox 
transgene (M25665, codon optimized) under control either of the constitutive active SFFV 
promoter or of the myelospecific miRNA-223 promoter.  
 
Figure 1 Schematic diagram of the used GT vectors for p47phox -deficient form of CGD. The vectors are γ -retroviral SIN vectors 
(plasmid configuration) with p47phox as transgene under control of the constitutive SFFV promoter or the myelospecific miRNA-
223 promoter.  
The following items are indicated: The SIN configuration is indicated by partial deletion of the U3 (∆) in the 3’ LTR and the 
presence of an internal promoter. SFFV, promoter/enhancer element of spleen focus forming virus; SD, splice donor site; Ψ, 
packaging signal; LTR, long terminal repeat; WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element; U3, R, 
U5 denote LTR subunits.   
 
GT of the p47phox -deficient form of CGD in p47phox -/- mice  
GT of the p47phox -deficient form of CGD was performed in p47phox -/- mice12. Enriched murine 
p47phox -/- lineage negative (Lin-) bone marrow (BM) cells were transduced ex vivo with one 
of the two γ-retroviral vectors shown above (figure 1) at molarity of infectivity (MOI) equal to 1 
according to prior titration. 24h later, the transduced BM cells were transplanted into lethally 
irradiated p47phox -/- mice (1E6 transduced BM cells per mouse).  
Engrafted mice were killed six weeks post-transplantation. Blood, spleen and BM of each 
individual mouse were isolated. The p47phox transgene expression in individual hematopoietic 
cell populations from each organ was detected by flow cytometry analysis (FACS) (see 
materials and methods). In Ly6G (GR1)+ granulocytes, p47phox transgene expression could 
be detected in mice treated with the SFFV vector or the miRNA-223 vector (figure 2). Those 
p47phox -/- mice which were treated with the myelospecific miRNA-223 SIN vector showed low 
or no p47phox transgene expression in monocytes, B-lymphocytes, T-lymphocytes in contrast 
to the constitutive SFFV control mice. In the ScaI/CD117+ stem- and progenitor cells 
enriched population the p47phox transgene expression was weak in the miRNA-223 mice 
group. The transduction efficiency of both vectors was below 25% confirming the majority of 
transduced cells contained statistically just one integration per cell13.  
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Furthermore, splenic T-lymphocytes, B-lymphocytes and monocytes were analyzed on a 
genetic level to validate the presence of virus integrants. Though p47phox expression was 
hardly detectable in all three cell populations, quantitative real time PCR (q-PCR) analysis 
clearly revealed the presence of the transgene. This finding is in line with the myelospecificity 
of the miRNA-223 promoter and excludes the possibility that all transduced stem- and 
progenitor cells differentiated exclusively to granulocytes.  
We further analyzed the absolute mean fluorescence intensity (MFI) of p47phox transgene 
expression in different hematopoietic cell populations to compare the transgene expression 
pattern of the two vectors. As expected, SFFV treated control mice showed a high absolute 
p47phox MFI in all hematopoietic cell populations measured (figure 3). A complete different 
result was obtained in case of the miRNA-223 group. These mice show a high p47phox MFI in 
blood and spleenic granulocytes, and a low or not detectable MFI in all other hematopoietic 
cell populations measured.  
Furthermore, we judged granulocytic development according to their CD11b upregulation. In 
CD11blow granulocytic progenitors p47phox was undetectable whereas mature CD11bhigh 
granulocytes showed a high p47phox expression. As was true for granulocytic progenitors, 
p47phox expression was low or undetectable in all cell population analyzed but in mature 
granulocytes.  
Altogether these results clearly show a myelospecific expression pattern of p47phox transgene 
in the miR-223 GT vector treated group.  
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Figure 2 p47phox transgene expression in p47phox -/- mice after retroviral GT. Lin- BM cells of p47phox -/- mice were ex vivo γ-
retrovirally transduced and transplanted into lethally irradiated p47phox -/- mice. 6 weeks after transplantation expression of 
p47phox transgene was monitored in individual hematopoietic cell populations by FACS analysis.  
Representative histograms of individual hematopoietic cell populations of blood and progenitor- and stemcells of BM from mice 
treated with SFFV-p47phox or miR-223-p47phox γ-retroviral vectors. Percentage (%) and mean fluorescence intensity (MFI) of 
p47phox positive cells are indicated.  
To avoid multicopy integrations, transduction rates were MOI=1; γ-retroviral titers were predetermined in the murine pro B cell 
line BA/F3 (ACC 300) by real-time q-PCR. MFI of the p47phox positive cells was measured by performing intracellular staining 
(ICS) of p47phox, followed by FACS.  
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Figure 3 Absolute MFI of p47phox transgene expression in p47phox -/- mice after retroviral GT. Lin- BM cells of p47-/- mice were 
ex vivo γ-retrovirally transduced and transplanted in lethally irradiated p47phox -/- mice. 6 weeks after transplantation p47phox 
transgene expression was monitored in individual hematopoietic cell populations of blood, spleen and BM by FACS analysis.  
(a) Absolute p47phox expression (FACS MFI) in individual hematopoietic cell populations isolated from blood.  
(b) Absolute p47phox expression (FACS MFI) in ScaI/CD117+ BM cells.  
(c) Absolute p47phox expression (FACS MFI) in individual hematopoietic cell populations isolated from spleen.  
MFI of p47phox positive and negative populations of each individual mouse was analyzed. Mean of percentage (%) of p47phox 
positive cells are indicated. Bars represent mean MFI values for each group. Values below 0.5% were beyond detection limit for 
quantitative MFI analysis.  
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Functional reconstitution of NADPH oxidase activity after GT in 
p47phox -/- mice 
The production of reactive oxygen species (ROS) in granulocytes can be monitored by the 
dihydrorhodamine-123 (DHR) assay. In this assay, the oxidation of non-fluorescent DHR 123 
to fluorescent rhodamine by ROS allows the detection of ROS producing cells by FACS 
analysis. Therefore we applied this methodology to analyze whether performed GT is able to 
restore the NADPH oxidase activity in granulocytes from treated p47phox -/- mice.  
Upon phorbol 12-myristate 13-acetate (PMA) stimulation, the shift in DHR signal (figure 4a) 
demonstrated that GT with the SFFV construct or the miRNA-223 construct resulted in the 
restoration of the NADPH oxidase activity. Analysis of the MFI within the DHR+ cell 
population showed even higher MFI for granulocytes from miRNA-223 and SFFV treated 
mice. The percentage of DHR+ cells reflects the expected transduction rate after 
transduction with MOI=1. 
Taken together, GT with myelospecific miRNA-223 γ-retroviral SIN vector resulted in clear 
myelospecific p47phox transgene expression compared to the constitutive SFFV control 
vector. Furthermore, the miRNA-223 γ-retroviral SIN vector could restore the NADPH 
oxidase equally effective as the SFFV control.  
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Figure 4 Reconstitution of the NADPH oxidase activity after GT. 6 weeks after transplantation with indicated vectors murine 
blood from each mouse was collected. The reconstitution of the NADPH oxidase activity upon PMA stimulation was analyzed by 
a DHR 123 oxidation assay within the Ly6G (GR1+) cell population.  
(a) Representative examples of FACS based DHR 123 oxidation analysis in Gr1+ cells. % and MFI of the DHR positive 
population within Ly6G (Gr1)+ murine neutrophils are indicated. C57bl6 wt are healthy control mice. 
(b) MFI of the DHR+ population in stimulated and unstimulated granulocytes. MFI of each analyzed mouse is shown. Bars 
represent mean values for each group. Mean of the percentage (%) of DHR+ cells within Ly6G (Gr1)+ murine neutrophils are 
indicated.  
 61
Discussion 
We successfully conducted a GT in p47phox -/- CGD mice using a myelospecific γ-retroviral 
SIN vector. In this vector, the transgene p47phox expression was under control of the 
myelospecific miRNA-223 promoter. In these mice a clear myelospecific transgene 
expression was observed. The rationale of this approach is based on the fact that observed 
clonal dominance and malignant transformation resulted from the transactivation of 
oncogenes adjacent to the viral integration site in stem and progenitor cells. Therefore, 
restricting the expression of therapeutic transgene to short-lived neutrophils will decrease the 
likelihood of side effects like malignant transformation. This view is supported by recent 
studies which determined the insertional genotoxicity in cell-culture systems14, 15. The 
insertional transforming capacity was significantly reduced for SIN vectors compared to 
corresponding LTR-driven vectors. In addition, the use of cellular promoters instead of 
retroviral enhancer-promoters in SIN vectors lowered the risk of genotoxic side effects.  
We previously analyzed the p47phox expression by our vector constructs ex vivo in stem cells 
and in granulocytes (chapter 1). The miRNA-223 promoter construct showed a significant 
upregulation upon granulocytic propagation ex vivo. The same was true in this in vivo study. 
A higher p47phox MFI could be observed in granulocytes compared to stem-and progenitor 
cells. Very low or no transgene expression could be observed in monocytes, B-lymphocytes 
and T-lymphocytes. These observations are in line with the description of miRNA-223 
transcription in wild type mice. Transcription of mature miRNA-223 was detected at low 
levels in pluripotent stem- and progenitor cells and monocytes, at high levels in peripheral 
blood granulocytes and not detected in B and T lymphocytes16. CD11b antigen has been 
identified as myelospecific differentiation marker. It is expressed selectively on the surface of 
neutrophils, mature monocytes, macrophages and natural killer cells17. In our hands, a high 
CD11b cell surface expression correlated with a high MFI p47phox transgene expression in 
the miRNA-223 group. This provides further evidence for myelospecific transgene 
expression.  
In our study, we have shown that the p47phox transgene is expressed and that it is functional. 
Isolated granulocytes from treated p47phox -/- mice showed a reconstitution of the NADPH 
oxidase function. In the DHR test the shift in the FACS signal for the miRNA-223 group was 
comparable to the shift observed for the strong and constitutively active SFFV promoter. As 
the p47phox subunit is involved in the regulation of the NADPH oxidase activity, one might 
hypothesize whether the p47phox subunit represents the limiting factor for NADPH oxidase. 
Artificial overexpression might therefore result in the exceeding of the natural NADPH 
oxidase activity.  
Already 5% of functional granulocytes are sufficient to protect CGD patient against 
infections18-20. Therefore GT, with the myelospecific miRNA-223 SIN vectors as it was used 
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in this study could lead to a sufficient number of corrected cells with sufficient NADPH 
oxidase activity. The presented combination of a γ-retroviral SIN vector with the 
myelospecific miRNA-223 internal promoter represents a major safety improvement as it 
minimizes the risk of malignant transformations of stem and progenitor cells as longterm 
effect of insertional mutagenesis. 
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Materials and methods 
Cell culture 
Non-adherent growing mouse pro B cell line BA/F3 (ACC 300) cells were grown in RPMI 
1640 (PAA Laborotories), 2% Antibiotic/Antimycotic (PAA Laborotories) supplemented with 
10ng/ml murine interleukin (IL) 3 (Peprotech). 
Murine p47phox -/- Lin- BM cells were harvested from femora and tibiae of p47phox -/- mice 
(B6(Cg)-Ncf1m1J/J) (Jackson Laboratory) and enriched by the “Lineage Cell Depletion Kit” 
(Miltenyi Biotec). Isolated BM cells were cultured in StemSpan H3000 medium (StemCell 
Technologies) supplemented with 50 ng/ml murine stem cell factor (mSCF) (Peprotech), 100 
ng/ml human Flt-3 ligand (Peprotech), 100 ng/ml human IL-11 (Peprotech), 20 ng/ml murine 
IL-3 (Peprotech), 1% penicillin/streptomycin (GIBCO), 2 mM glutamine (GIBCO)21 and 2% 
FBS (Hyclone Thermoscientific).  
 
Cloning of γ-retroviral vectors and production of infectious particles  
The γ-retroviral pSERS11M8delN91s SIN vector (a derivate of the SERS11.SF.GFP.W11, 
kindly provided by M. Grez, Georg Speyer, Frankfurt) was used as basic construct. 
pSERS11M8delN91s SIN vector contains the internal mrp8 promoter 5’ to the gp91phox 
coding reading frame (CRF). In the first step a Sal I-restriction site was inserted between the 
gp91phox CRF and the Woodchuck hepatitis virus post-transcriptional element (WPRE) by in 
vitro mutagenesis (Stratagene). Then, the gp91phox CRF was substituted by human p47phox 
CRF (M25665, codon optimized by GENEART) by BamH1/SalI (New England Biolabs 
(NEB)) restriction digestion. The miRNA-223 promoter was amplified from the plasmid “223-1 
gps W” (kindly provided from M. Grez, Georg-Speyer-Haus, Institute for biomedical research, 
Frankfurt, Germany) and cloned into this vector by replacing the NdeI/BamHI mrp8 promoter 
fragment. The constitutive active promoter sequence SFFV was amplified from 
SERS11.SF.GFP.W (kindly provided from M. Grez, Georg-Speyer-Haus, Institute for 
biomedical research, Frankfurt, Germany).  
For construction, the recombinant plasmids were introduced by electroporation (Gene Pulser, 
Biorad) or heat shock into E. Coli Top-10 competent cells (Invitrogen). DNA manipulations 
were performed according to standard procedures by using commercial kits (Qiagen, 
Macherey-Nagel, Genomed). All resulting constructs were controled by restriction digestion 
followed by agarose gel electrophoresis. The cloning sites and flanking sequences of the 
resulting constructs were confirmed by DNA sequencing (ABI PRISM 3130xl Genetic 
Analyzer, Applied Biosystems (AB)).  
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Ecotropic infectious particles were generated by transient transfection of Phoenix (ΦE) cells 
(ACC 3444). These cells are derived from human embryonic kidney (HEK) 293T cells by 
stable integration of a plasmid carrying the moloney murine like virus (MLV) gag-pol CRFs 
and with an ecotropic MLV env expressing plasmid. In a 10 cm petridish, 70-80% confluent 
Phoenix E cell layers were co-transfected by 4µl TransIT-293 reagent (Mirus LCC Bio) per µg 
(total DNA), 10µg pUMVC (encoding γ-retroviral GagPol), 4µg M187 (encoding ecotropic 
envelope) and 40µg gene transfer vector. Infectious particle containing cell culture 
supernatants were collected 24h, 48h, 60h after transfection and sterile filtered (Millex 
Syringe Driven Filter units, 0.45 µm pore size (Millipore)). The supernatant was concentrated 
(30X) (Amicon-Ultra 15 centrifugal units, 1500g, 18min at RT) from 15ml to an end volume of 
500µl and frozen immediately in form of aliquots a 20µl at -80°C. For titration, serial dilutions 
of viral supernatants were used to infect mouse pro B cells BA/F3 (ACC 300) in the presence 
of protamine sulfate (8µg/ml, Sigma). Virus supernatant was thawed and taken immediately 
for transduction (spinoculation for 90 min, 2500 RPM, at 32°C). One week after transduction 
DNA was extracted from the cell pellets by „DNeasy blood and tissue kit“ (Qiagen). The 
vector copy number was quantified by real-time q-PCR with 50-200 ng template DNA in a 
reaction volume of 25µl. The set of primers and probes used for the analysis were as follows 
(table 2): 
 
detect primers/probes sequence 
final 
concentration
, nM 
company 
forward primer 5’-AGAGGGAAATCGTGCGTGAC-3’ 500 Microsynth 
reverse primer 5’-CAATAGTGATGACCTGGCCGT-3’ 500 Microsynth 
actb (encoding β-
actin) 
(endogenous control) probe VIC-CACTGCCGCATCCTCTTCCTCCC-
MGB 
200 AB 
forward primer 5’-TTTCTGGGACTTTCGCTTTCC-3’ 500 Microsynth 
reverse primer 5’-AGGCGGCGATGAGTTCTG-3’ 500 Microsynth 
WPRE 
probe FAM-CCTCCCGATCGCC-MGB 200 AB 
Table 1 Primers and probes used for real-time q-PCR.  
 
We generated a standard curve by combining DNA from BA/F3 cells without and with one 
integration per cell (kindly provided from M. Grez, Georg-Speyer-Haus, Institute for 
biomedical research, Frankfurt, Germany). TaqMan reactions were carried out in triplicates in 
an ABI Prism 7700 HT Sequence Detection System (AB). Transduction of HSC and different 
cell lines (e.g. BA/F3 cells) with one and the same virus supernatant resulted in different 
transduction efficiencies. Therefore we determined the factor between the titers related to 
BA/F3 cells and to HSC. Murine Lin- BM cells and BA/F3 cells were transduced with the 
SFFV control virus supernatant and analyzed 5 days later by intracellular p47phox staining 
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measured by FACS (BD). The titer in BA/F3 cells was calculated to be 1.6 fold higher 
compared to HSCs.  
 
Detection of transgene expression in individual hematopoietic cell 
populations 
p47phox expression was measured by performing ICS with the anti-p47phox antibody (clone 1), 
APC-labeled by BD-services. For combined staining of surface markers and intracellular 
p47phox, the cells were first blocked with mouse Fc-block (BD) (clone 2.462) for 10min at 4°C, 
incubated with the surface antibodies (see table 2) for 1h at 37°C and washed twice. 
Thereafter, p47phox was stained with APC anti-p47phox using the Cytofix/Cytoperm Kit (BD) 
according to manufacturer’s instructions. APC mIgG1 Isotyp (clone X40, BD) antibody was 
utilized as isotype control in intracellular staining.  
 
Detection of 
murine 
antibody clone company 
FITC anti-Ly6G 1A8 BD 
granulocytes 
PE anti-Ly6G and Ly6C RB6-8C5 BD 
FITC anti-Ly6G 1A8 BD 
monocytes 
PE anti-Ly6G and Ly6C RB6-8C5 BD 
B-lymphocytes FITC anti-CD45R/B220 RA3-6B2 BD 
T-lymphocytes PE anti-CD3 17A2 BD 
neutrophils, 
monocytes, 
natural killer cells 
PE CD11b M1/70 BD 
Ly-6A/E ScaI E13-161.7 BD progenitor-and 
stemcells FITC CD117 2B8 ebioscience 
PE ratIgG2a, κ R32-95 BD 
isotype control 
FITC ratIgG2b, κ A95-1 BD 
 
Table 2 Surface antibodies utilized for detection of individual murine hematopoietic cells.  
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Determination of γ-retroviral copy number by q-PCR in p47phox -/- 
mice 
B-lymphocytes, T-lymphocytes and monocytes from each p47phox -/- mouse were sorted from 
5*106 splenocytes by live, sterile cell sorting (FACS ARIA, BD).  
Genomic DNA was extracted from the cell pellets by „Qiamp DNA Mini kit“ (Qiagen). The 
vector copy number was quantified by two parallel real-time q-PCR reactions in one tube with 
20-50 ng template DNA in a reaction volume of 20µl. The set of primers and probes used for 
the analysis were as follows (table 3): 
 
detect primers/probes sequence 
final 
concentration
, nM 
company 
forward primer 5’-ATTGCCACCACCTGTCAACT-3’ 300 Operon 
reverse primer 5’-GCAACCTAGCCCCTGTCC-3’ 750 Operon 
actb (encoding β-
actin) 
(endogenous control) probe RED-CACTGCCGCATCCTCTTCCTCCC-
BHQ2 
80 Operon 
forward primer 5’-ATTGCCACCACCTGTCAACT-3’ 200 Operon 
reverse primer 5’-GCAACCTAGCCCCTGTCC-3’ 200 Operon 
WPRE 
probe RED-CACTGCCGCATCCTCTTCCTCCC-
BHQ2 
50 Operon 
Table 3 Primers and probes used for real-time q-PCR.  
 
We generated a standard curve by combining DNA from BA/F3 cells without and with one 
integration per cell (kindly provided from M. Grez, Georg-Speyer-Haus, Institute for 
biomedical research, Frankfurt, Germany). TaqMan reactions were carried out in duplicates 
in a LighCyler 480 II (Roche).  
 
Transduction of murine p47phox -/- Lin- BM cells 
p47phox -/- Lin- BM cells were isolated using the lineage cell depletion kit (Miltenyi). The BM 
cells were cultured for 2 to 3 days in StemSpan H3000 supplemented with cytokines (see cell 
culture section). Cell culture plates were precoated with Retronectin (TaKaRa) by incubation 
with 10 µg/cm2 at RT for 2h followed by HSA incubation for 10 min. Frozen titered γ-retroviral 
supernatants were thawed, prediluted in StemSpan H3000 and loaded onto the precoated 
plates by centrifugation (3000 RPM for 30 min at 4°C). Then, p47phox -/- Lin- BM cells were 
seeded onto virus-loaded plates and cultured for 2 to 3 days in cytokine supplemented 
StemSpan H300021.  
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Transplantation of transduced Lin- p47phox -/- BM cells into  
p47phox -/- mice  
4-6 weeks old p47phox -/- mice were lethally irradiated with 950cGy. Per mouse 1E6 γ-
retrovirally transduced Lin- BM cells were injected 4 hours later via tail vein injection. All mice 
received neomycin (SIGMA) treatment as additive in the drinking water (1.67 mg/ml) for six 
weeks. After six weeks, murine blood from the tail vein was analyzed for respiratory burst 
activity (see analysis of respiratory burst activity). Then, mice were euthanized with CO2. 
Blood, spleen, BM from each mouse were taken immediately and analyzed for p47phox 
expression by FACS. Prior to surface and intracelluar FACS staining, erythrocytes in blood 
were lysed by ammonium chloride lysing buffer (Kantonsapotheke Zürich). Splenocytes were 
harvested by passing through a 70µM cell strainer (BD) followed by ammonium chloride 
treatment. BM cells were flushed out from femora and tibiae followed by erythrocyte lysis. All 
mice were kept at the Institut für Labortierkunde of University hospital Zurich under specific 
pathogen-free conditions. All animal procedures were conducted in accordance with the 
ethical guidelines of Animal Studies Ethics Committee and in concordance with Swiss animal 
protection law. 
 
Analysis of respiratory burst activity of neutrophils from murine 
blood samples 
For analyses of respiratory burst activity, the dihydrorhodamine assay (DHR) 123 was 
carried out as described8 with a few modifications. We combined the FACS based DHR 
assay with the analysis of cell surface markers. 100-200µl mouse blood were collected by tail 
venisection. Murine neutrophils were identified by prestaining with PerCP-Cy5.5 anti-Ly-6G 
and Ly-6C (clone RB6-8C5, BD) for 10min at 4°C. Then erythrocytes in blood were lysed 
with pre-cooled ammonium chloride lysis buffer for 10 min on ice. Afterwards, the cells were 
washed and incubated in 500µl Hanks’ Buffered Saline Solution (HBSS) (PAA Laboratories) 
with Ca and Mg supplemented with 0.5% HSA, CSL Behring), 7.5 mM Glucose (SIGMA), 2µl 
catalase (1000U/ml, SIGMA), 10 µl DHR (stock 29mM, 1:1000 diluted, SIGMA) for 15min at 
37°C. Blood cells were stimulated with 1µg/ml PMA (SIGMA) for 15min at 37°C in presence 
of DHR. A shift in DHR 123 fluorescence was measured by flow cytometry (BD) within 30 min 
after stimulation.  
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Abstract  
Chronic Granulomatous Disease (CGD) comprises a group of five primary 
immunodeficiencies characterized by an impaired respiratory burst activity of myeloid cells. 
We are currently developing a gene therapy (GT) vector for the p47phox-deficient form of 
CGD. Classic intracellular immunostaining (ICS) of the cytoplasmic p47phox transgene 
product, however, interferes with respiratory burst activity. Here we report a new system for 
measuring p47phox expression: A single open reading frame (ORF) encoding the surface 
marker protein ∆LNGFR (truncated low-affinity nerve growth factor receptor) linked to the 
p47phox transgene via the 2A oligopeptide co-expression technology. Translation generates 
two discrete products: p47phox localizing to the cytoplasm and [∆LNGFR-2A] localizing to the 
cell surface. Six weeks after transplantation of transduced autologous hematopoietic stem 
cells (HSC) into p47phox -/- mice, the intracellular p47phox FACS signal intensities 
corresponded with surface ∆LNGFR staining in monocytes, B cells, T cells and ScaI+ bone 
marrow (BM) cells in vivo. The p47phox cleavage product restored NADPH-oxidase activity in 
granulocytes differentiated from transduced p47phox -/- murine hematopoietic stem cells 
(HSC) ex vivo, in murine granulocytes/monocytes in vivo, and in transduced human 
monocyte derived macrophages from p47phox-deficient CGD patients. In conclusion this new 
marker system allows highly efficient, indirect detection of cytoplasmic transgene products by 
FACS surface staining. 
 
Introduction 
CGD results from impaired respiratory burst activity caused by a mutated phagocyte NADPH 
oxidase complex 1. This enzyme complex consists of two membrane spanning subunits 
(gp91phox and p22phox) plus three cytosolic components (p47phox, p67phox and p40phox). 
Approximately 60% of all CGD cases have been estimated to result from mutations in the 
gene encoding gp91phox with an additional 30% caused by gene mutations encoding p47phox 
2.  
The p47phox subunit is a cytoplasmic protein recruited to the transmembrane NADPH-oxidase 
complex upon respiratory burst induction. Currently, a GT vector for the p47phox-deficient form 
of CGD is being developed. Critically, the efficacy of GT should be monitored via the 
detection of transgenic p47phox expression.  
Since cellular integrity is an absolute pre-requisite for the induction of phagocytic NADPH-
oxidase activity, it is impossible to combine functional analyses with the detection of p47phox 
protein by immunostaining. To overcome this limitation we developed a system in which the 
expression of the cytoplasmic transgene product is linked to, and can be monitored by, the 
coexpression of a cellular surface marker. A single ORF was created encoding the 
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therapeutic p47phox transgene linked to the ∆LNGFR surface marker protein via the Foot and 
Mouth Disease Virus (FMDV) 2A peptide. In this 2A-mediated co-expression system the 
detection of the surface marker provides a indirect measure for the expression of the 
cytoplasmic transgene product.  
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Results 
The ∆LNGFR surface marker and the therapeutic p47phox transgene 
product are synthesized in a 1 : 1 ratio 
The p47phox marker construct was assembled to encode a single, self-processing, polyprotein 
comprising three domains; (i) an N-terminal domain of ∆LNGFR (NM_002507; nts. 114-944), 
(ii) the 2A oligopeptide (31aa; X00871; nts. 3483-3575) and (iii) the C-terminal domain 
comprising the p47phox subunit of the NADPH-oxidase (M25665, codon optimized) (figure 1a). 
Cotranslational ribosomal ‘skipping’ mediated by 2A is predicted to produce two translation 
products: the transmembrane ∆LNGFR fused to the 2A peptide ([∆LNGFR-2A]), and the 
cytoplasmic p47phox protein with an N-terminal proline (P-p47phox).  
To test this marker system and its influence on the transgenic protein activity, murine 32D 
hematopoietic progenitor cells (German Collection of Microorganisms and Cell Cultures 
(DSMZ), DSMZ no.: ACC 411) were transduced using a recombinant gammaretrovirus 
encoding the marker construct. Transgene expression was confirmed by FACS analysis. 
Surface staining of [∆LNGFR-2A] and staining of intracellular p47phox demonstrated a 
transduction rate of 22% in each case. As expected, surface [∆LNGFR-2A] staining plus 
intracellular p47phox double-staining revealed exclusively [∆LNGFR-2A]/P-p47phox double-
positive and double-negative cells, whereas P-p47phox could not be detected by surface 
staining (figure 1b). 
To confirm co-translational ‘cleavage’, protein extracts of ∆LNGFR-2A-p47phox transduced 
32D cells were analyzed by Western blotting. P-p47phox linked to [∆LNGFR-2A] showed a 
very weak band with identical molecular weight in both blots, corresponding to the expected 
size of the uncleaved polyprotein (figure 1c, filled triangles). Strong bands were detected for 
both cleavage products [∆LNGFR-2A] and P-p47phox (figure 1c, open triangles), with masses 
of ~65kDa and ~47kDa, corresponding to the control extracts. Signal intensities of both 
Western blots indicate that >98% of the transgene encoded proteins were synthesized as 
separated (cleaved) proteins due to ribosome ‘skipping’ mediated by the 2A sequence.  
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Figure 1 Cloning strategy and detection of the two 
translation products of the marker system.  
(a) Integrated gammaretroviral SIN-vector with 
constitutive spleen focus-forming virus (SFFV) promoter 
driving ∆LNGFR-2A-p47phox expression (S: LNGFR signal 
peptide, E: LNGFR extracellular domain,  
T: LNGFR transmembrane domain, C: shortened LNGFR 
cytoplasmic domain, 2A: FMDV 2A peptide (31aa), 
WPRE: Woodchuck hepatitis virus post-transcriptional 
regulatory element).  
(b) FACS analysis of transduced 32D progenitor cells 
(ICS: intracellular staining).  
(c) Western blot analysis of transduced 32D cells 
detecting p47phox and LNGFR. 32D cells transduced with 
p47phox  and a monoclonal clone derived from transduced 
PLB985 cells expressing ∆LNGFR were used as positive 
controls. Filled triangle: ∆LNGFR-2A-p47phox fusion 
protein, open triangle: ∆LNGFR fused to 30aa 2A peptide 
([∆LNGFR2A]), and the cytoplasmic p47phox protein with 
an N-terminal proline (P-p47phox) translation products.  
 
 
 
 
 
The ∆LNGFR surface epitope correlates with the presence of the 
cytoplasmatic p47phox protein in vivo 
Lineage-negative (Lin-) BM cells from p47phox -/- mice were isolated, retrovirally transduced 
and reinfused into lethally irradiated p47phox -/- mice. The transduction rate was 4.2%, as 
determined by p47phox ICS of Ly-6G(1A8)-positive granulocytes obtained after ex vivo 
differentiation of transduced BM cells in liquid cell culture. Six weeks after reinfusion into 
p47phox -/- mice, p47phox and ∆LNGFR expression was analyzed. As expected, random 
integration into the genome resulted in heterogeneous expression levels, also known as 
‘position-effect variegation’ 3. 
In blood the mixed granulocytic/monocytic population of Ly-6G and/or Ly-6C-positive cells 
recognized by anti-Ly-6G/Ly-6C mAb RB6-8C5 revealed populations with varying p47phox and 
∆LNGFR stain intensities (figure 2a). In the spleen, granulocytes and monocytes were 
identified separately by anti-Ly-6G/Ly-6C (mAb RB6-8C5) and anti-Ly-6G (mAB 1A8) double 
staining. Granulocytes (RB6-8C5+/1A8+) varied in ∆LNGFR staining intensity (figure 2b). In 
splenic monocytes (RB6-8C5+/1A8-), however, the intracellular p47phox signal ran in parallel 
to the surface ∆LNGFR staining (figure 2c). The same parallel between the p47phox and 
∆LNGFR signals were observed within a hematopoietic stem- and progenitor cell enriched 
population of ScaI+ BM cells (figure 2d), in splenic B220+ B-cells (figure 2e) and in CD3+ T-
cells (figure 2f). Taken together, with the exception of granulocytes, the intracellular p47phox 
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FACS signal ran in parallel to the ∆LNGFR surface marking in non ∆LNGFR/p47phox double-
negative cells.  
 
 
 
Figure 2 FACS analysis of murine blood, spleen and BM 
cell populations six weeks after GT 
Surface ∆LNGFR / intracellular p47phox double-staining of 
(a) mouse blood gated for Ly-6G and/or Ly-6C-positive 
cells (mAb clone RB6-8C5) i.e. mainly granulocytes and 
monocytes, of (b) splenic granulocytes (Ly-6G/Ly-6C 
(mAb RB6-8C5) / Ly-6G (mAb 1A8) double positive 
cells), of (c) splenic monocytes (Ly-6G/Ly-6C  
(mAb RB6-8C5) positive / Ly-6G (mAB 1A8) negative 
cells), of (d) hematopoietic stem- and progenitor cell 
enriched population of ScaI+ BM cells, of (e) splenic 
B220+ B-cells and of (f) splenic CD3+ T-cells. 
 
 
 
 
 
 
The P-p47phox translational-skipping product restores respiratory 
burst activity in vitro and in vivo 
We next investigated whether the P-p47phox translational skipping product was able to restore 
respiratory burst activity. The ∆LNGFR-2A-p47phox retrovirus vector was used to transduce 
Lin- BM cells obtained from p47phox-/- mice and subsequently differentiated to granulocytes 
ex vivo. Granulocytes derived from untransduced and transduced p47phox-/- Lin- BM cells 
were stimulated with PMA and the NADPH-oxidase activities visualized by a nitroblue 
tetrazolium (NBT) assay. Within the transduced cell population the reduction of NBT to its 
formazan derivative in individual cells yielded intracellular blue/black precipitates 
demonstrating restoration of the NADPH-oxidase activity (figure 3b) - not observed in the 
negative-control (figure 3a). 
Six weeks after reinfusion of transduced Lin- BM cells into p47phox -/- mice, blood samples 
were analyzed for respiratory burst activity. Mouse blood was stained with the Ly-6G/Ly-6C 
specific mAb clone RB6-8C5. Ly-6G/Ly-6C-positive cells were analyzed for ∆LNGFR 
expression and their respiratory burst activity upon PMA stimulation was determined by the 
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FACS based dihydrorhodamin-123 (DHR) oxidation assay. As expected, unstimulated Ly-
6G/Ly-6C+ blood cells were partially ∆LNGFR-positive and DHR-negative (figure 3c). Upon 
stimulation, the shift in DHR signal demonstrates activation of the NADPH oxidase and 
reconstitution of respiratory burst activity in neutrophils and monocytes derived from 
transduced stem cells in vivo (figure 3d). Those Ly-6G/∆LNGFR-positive cells which do not 
show a shift in DHR signal are expected not to represent monocytes or granulocytes as the 
anti- Ly-6G/Ly-6C mAb clone RB6-8C5 also detects Ly-6C-positive dendritic cells and 
subpopulations of lymphocytes4 with no respiratory burst activity. 
Recently it has been reported that gammaretroviral transduction of macrophages is possible, 
although with low efficiency5. Therefore we analyzed the activity of the construct in human 
macrophages derived from a p47phox-CGD patient (figure 3e,f,g). Monocytes were isolated 
and differentiated into macrophages for seven days. Macrophages were then transduced, 
and analyzed for NADPH-oxidase activity three days later. As expected5, transduction 
efficiency was low. As in the murine model, we detected NBT-positive cells in transduced 
human cells. This clearly indicates that the cytoplasmic P-p47phox translational skipping 
product is able to restore the NADPH-oxidase activity not only in primary murine cells (both 
ex vivo and in vivo) but also in derived primary human cells. 
 
 
 
Figure 3 Functional reconstitution of respiratory burst activity by the P-p47phox 
translation product.  
Light microscopic evaluation of granulocyte nitroblue tetrazolium (NBT) assay 
prepared by cytospin. Intracellular dark precipitates indicate respiratory burst 
activity. Granulocytes derived from untransduced (a) and ∆LNGFR-2A-p47phox 
transduced (b) Lin- BM cells from p47phox -/- mice after differentiation in liquid 
cell culture (Scale bars = 50µm). 
(c, d) Combined staining of Ly-6G/Ly-6C+ granulocytes and monocytes in 
mouse blood and functional analysis of respiratory burst activity by 
dihydrorhodamin-123 (DHR) assay. Please note that Ly-6C recognized by mAb 
clone RB6-8C5 is also present on dendritic cells and subpopulations of 
lymphocytes4 without respiratory burst activity. (c) DHR test of unstimulated 
and (d) PMA stimulated Ly-6G/Ly-6C+ cells in mouse blood six weeks after 
∆LNGFR-2A-p47phox GT. 
NBT assay on macrophages from healthy control (e), or from untransduced (f) 
and ∆LNGFR-2A-p47phox transduced (g) macrophages derived from a  
p47phox-deficient CGD patient (Scale bars = 100µm). Inserts in (b) and (g) 
show NBT-positive cells in higher magnification.  
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Discussion 
The 2A co-expression methodology was applied to overcome the limitation that detection of 
the cytoplasmic p47phox transgene product interferes with functional analysis. Our expression 
strategy expands the panel of intracellular marker proteins from co-expressed GFP6 to 
surface epitopes in general. A perfect marker molecule must consist of a transmembrane 
domain plus an extracellular epitope. Such a marker should be; (i) biologically inert, (ii) not 
participate in signal transduction and (iii) not dimerize with transmembrane receptors (and 
thereby potentially contribute to signal transduction processes). Finally, in order to avoid 
immunogenicity after human GT the marker molecule should be of human origin and 
normally expressed in a tissue different from the GT target tissue. In the present vector the 
expression of the ∆LNGFR surface marker was linked with the expression of a cytoplasmic 
p47phox transgene. 
Double labeling of intracellular p47phox and surface standing  ∆LNGFR in 32D hematopoietic 
progenitor cells revealed their co-expression in cells transduced with the retroviral vector. 
The signal intensities of both Western blots indicate that >98% of the transgene encoded 
proteins were synthesized as separated (cleaved) proteins due to ribosome ‘skipping’ 
mediated by the 2A sequence. Just 16-20aa of FMDV 2A possess skipping activity7, 
although N-terminal extensions increase the activity up to >99% for 2A sequences of 33aa or 
longer6, 8, 9. The cleavage efficiency of the present construct containing 31aa of 2A is 
consistent with efficiencies previously reported. Due to the high cleavage efficiency of our 
marker system the detection of the [∆LNGFR-2A] surface marker provides a direct measure 
for the presence of the cytoplasmic p47phox transgene product. Moreover, the cleavage 
process of a translation product encoded in a single open reading frame dictates a 1:1 ratio 
of the two cleavage products. Our mouse experiments showed position-effect variegation ran 
in parallel for the therapeutic protein product (intracellular p47phox) and the cell surface 
marker  (∆LNGFR) in hematopoietic stem/progenitor cells, monocytes, T cells and B cells. 
Surprisingly, the intracellular p47phox / surface ∆LNGFR double staining revealed individual 
populations in granulocytes differing in ∆LNGFR staining intensities. The explanation for this 
observation is unclear and a detailed analysis ongoing. 
The use of intracellular ribosomal entry sites (IRES) represents an alternative approach to 
generate multicistronic expression from one vector. In a bicistronic IRES-based vector, 
translation initiation of the 5’ coding reading frame (CRF) requires the m7G cap and its 
associated protein factors, whereas the 3’ CRF is thought to be translated cap-independently 
by direct recruitment of the ribosome to the IRES element. Due to different efficiencies of 
translation initiation the ORF downstream of IRES is consistently less expressed than the 
ORF upstream of IRES 10. Compared to IRES based biscistronic expression, GFP co-
expression by the 2A strategy was approximately four times higher11.  
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Additionally, the packaging capacity is limited in retroviral vectors12. Regarding size 
limitations the 19AA/57nt 2A sequence is advantageous compared to e.g. 470nt IRES of 
FMDV or the 640nt IRES of Poliovirus. Furthermore, both IRES sequences were reported to 
result in retroviral titer reduction whereas 2A did not13. One reason for this reduction in 
retroviral titers by IRES sequences might be their secondary structure. The hepatitis C virus-
like picornavirus IRES elements are known to possess extensive RNA secondary structure 
identified as substrate for the Dicer ribonuclease14. A ribonucleolytic cleavage by Dicer would 
interfere with the retroviral life cycle. 
In our vector, ∆LNGFR serves as a membrane standing marker epitope indirectly 
representing the cytoplasmic P-p47phox translation product. The ∆LNGFR marker protein was 
used previously until Li and coworkers reported one leukemic transformation event in a 
single mouse by a ∆LNGFR containing gammaretroviral LTR-driven (non-SIN) vector after 
integration into the murine evi1 gene associated with Evi1 expression15. However, data 
amassed from 17 independent investigators from >300 mice having received BM 
transplantation of HSCs transduced with ∆LNGFR expressing retroviral vectors revealed no 
adverse events. This weakens the argument for an increased frequency of insertional 
oncogenesis by ∆LNGFR16. Malignant transformation is a multi-step process17, in which 
retroviral insertion may be just one event18. Evi1 over-expression resulting from retroviral 
insertion near evi1 has been reported to interact with mutant aml1 to induce MDS/AML19. 
Interestingly, ∆LNGFR had been used in two clinical trials as marker molecule for the 
gammaretroviral transduction of patient T-cells (mentioned in20). Cumulatively, the 46 
patients treated since 1994 received a total of >1011 genetically modified T-cells. Expansion 
(up to 40% of circulating cells) and long-term persistence (>10 years) of transduced T-cells 
were observed in these patients in the absence of any adverse event or toxic effect related to 
the gene transfer procedure. A detailed follow up after 10 years of two patients revealed that 
despite the observed frequency of insertional gene activation, there was no evidence of 
clonal selection or preferential survival of transduced T cells20. These facts lead to the 
conclusion that the leukemia was induced in Li’s mouse15 by vector LTR-mediated Evi1 over-
expression only in combination with an undetected preexisting or acquired additional hit, but 
not by ∆LNGFR alone. ∆LNGFR thus represents a useful marker protein not only for 
preclinical gene transfer studies involving therapeutic cytoplasmic proteins but might 
potentially also be applied in future clinical GT using retroviral SIN vectors. Nevertheless, the 
presented cloning strategy is not limited to ∆LNGFR. The 2A methodology can be adapted to 
other transmembrane marker proteins under maintenance of the 1:1 ratio of synthesized 
therapeutic protein and marker protein. After cotranslational ribosomal ‘skipping’ the 
cytoplasmic skipping product consisted of the therapeutic p47phox transgene product N-
terminally prolonged by one proline (P-p47phox). We have shown by functional assays that the 
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biological activity of p47phox is not affected by the addition of an N-terminal proline residue 
derived from the 2A sequence combining ∆LNGFR and p47phox. 
In summary, the presented cytoplasmic/surface marker co-expression technology allows 
highly efficient, indirect detection of cytoplasmic transgene products by FACS surface 
staining. The cloning strategy can be easily adapted to different cytoplasmic therapeutic 
transgene products and alternative surface marker proteins, and it provides a useful tool for 
the detection of cytoplasmic transgene products optionally applied for GT monitoring. 
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Materials and Methods 
Vectors 
The gammaretroviral vector backbone was derived from self-inactivating (SIN) 
gammaretroviral SERS11.SF.gp91.W (gift M.Grez). The transgene was exchanged against a 
cassette containing the N-terminal domain of ∆LNGFR (NM_002507; nts. 114-944), the 2A 
oligopeptide (31aa; X00871; nts. 3483-3575) followed by the p47phox subunit of the NADHP-
oxidase (M25665, codon optimized). 
 
Virus production and transduction 
For retroviral vector production PhoenixE cells or 293T cells were cotransfected with the 
∆LNGFR-2A-p47phox gammaretroviral self-inactivating (SIN)-vector together with pUMVC plus 
pMD2.VSV.G or M187 (gift of M. Grez) in the presence of 10 µM chloroquin (SIGMA). Cell 
free virus supernatant was concentrated using Amicon-15 centrifugal filter devices with 
100.000kDa cut off (Millipore).  
For transduction of 32D cells the viral particles and 105 cells were spinoculated for 90min, 
400g at 32°C with 8 µg/ml protamine sulfate (SIGMA) and incubated overnight. For 
transduction of mouse Lin- BM cells, the viral particles were spinoculated (400g, 30min, 4°C) 
onto fibronectin-coated tissue culture plates. The Lin- BM cells were prestimulated for 2 
days, spun down onto the virus preloaded plates21 and kept in culture for three days. 
For transduction of human monocyte derived macrophages, monocytes were isolated from 
human whole blood using CD14 microbeads (Miltenyi Biotec), allowed to settle for 3h and 
cultured in RPMI, 10 % FBS, 1 µM GM-CSF for 7 days. Then, viral particles were 
spinoculated onto the adherent macrophages (90min, 400g at 32°C)5. 
 
Antibodies 
FITC-anti-LNGFR (cloneME20.4-1.H4) and FITC anti-CD3ε (clone145-2C11) were from 
Miltenyi Biotec. PE anti-LNGFR (clone C40-1457), FITC anti-Ly-6G (1A8), PerCP-Cy5.5 anti-
Ly-6G and Ly-6C (clone RB6-8C5), PE anti-Ly-6A/E ScaI (E13-161.7) and FITC anti-
CD45R/B220 (clone RA3-6B2) were from BD Biosciences as was anti-p47phox antibody 
(clone 1) which was APC-labeled by BD-services. 
Murine cells were first blocked with Fc block anti-CD16/CD32 (clone 2.4G2, BD). For 
combined surface/intracellular staining cells were incubated with surface antibody for 1h, 
washed twice, followed by intracellular staining with anti-p47phox-APC using the 
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Cytofix/Cytoperm Kit (BD) according to the manufacturer’s instructions. Flow cytometry 
analyses were performed with FACS Calibur (BD).  
Western Blot analyses were performed using ECL Advanced Western Blot Detection Kits 
(GE Healthcare). 
 
Mice 
p47phox -/- mice (B6(Cg)-Ncf1m1J/J) were obtained from the Jackson Laboratory (Bar Harbor, 
Maine, USA). Mice were maintained under specific pathogen-free conditions. Housing and 
experimental protocols were in accordance with the Swiss animal protection law and in 
compliance with the regulations of the Veterinaeramt, Kanton Zurich. For isolation of Lin- BM 
cells, BM was harvested from femurs/tibias and enriched by the “Lineage Cell Depletion Kit” 
(Miltenyi Biotec).  
For BM transplantation 4-6 weeks old mice were irradiated with 950cGy. Per mouse, 1E6 
gammaretrovirally transduced Lin- BM cells were injected 4 hours later via tail vein injection. 
Mice received prophylactic neomycin (SIGMA) as additive in drinking water (1.67 mg/ml). For 
ex vivo granulocyte differentiation, Lin- BM cells were washed two days after transduction 
and cultured in RPMI, 20% FBS, 100ng/ml G-CSF and 10ng/ml IL-3 for 12 days.  
 
Functional assays 
The NBT assay and dihydrhodamine assay (DHR) 123 were carried out as described22 with 
one modification: To identify murine granulocytes/monocytes in the DHR 123 assay we first 
stained the blood samples using mAB clone RB6-8C5 and conducted the assay with the 
prestained samples. FACS analysis was carried out on a FACS CaliburTM (Becton Dickinson 
AG, Allschwil, Switzerland) and images were captured by a Leica DM IL HC microscope 
(Leica Microsystems, Heerbrugg, Switzerland). 
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General Discussion 
Retroviral GT provides a new approach to treat X-CGD (g91phox-deficiency)1, adenosine 
deaminase deficient immunodeficiency (ADA-SCID)2 and X-linked severe combined 
immunodeficiency (SCID-X1)3. This is highly desired, as for CGD patients the present state-
of-art treatment is the bone marrow transplantation (BMT). BMT has been associated with 
unacceptably high rates of morbidity, mortality and graft failure, except in very selected cases 
in which an HLA-identical donor is available4, 5. However, the first clinical GT studies for X-
CGD and SCID were accompanied with clonal dominance1, 6, 7 or leukemic progression8 as 
long term effects of transactivation events. The observed severe side effects resulted from 
the transactivation of oncogenes adjacent to the viral integration site by retroviral enhancer 
activity in stem- and progenitor cells8-10. These observations demand the development of 
safer vector systems. For the p47phox-deficent form of CGD, representing 30%11, 12 of all CGD 
patients, BMT is the only available therapy at present with no GT vector being available. 
Therefore, in this thesis, a safer γ-retroviral GT vector for correction of p47phox-CGD was 
developed.  
 
To minimize the risks of transactivation we utilized γ-retroviral SIN vectors13, 14 for GT of 
p47phox -/- CGD (chapter 1,2). In these vectors the viral promoter/enhancer elements are 
inactivated upon integration. The transgene expression is driven by an internal tissue-specific 
promoter element which ideally lacks enhancer activity and restricts transgene expression to 
terminally differentiated granulocytes/monocytes. Restricting the expression of the 
therapeutic transgene to short-lived neutrophils will decrease the likelihood of side effects 
like clonal dominance or malignant transformation in stem- and progenitor cells. This view is 
supported by recent studies which determined insertional genotoxicity in cell-culture 
systems15, 16 and in vivo tumor-prone mouse models17. The insertional transforming capacity 
was significantly reduced by SIN vectors compared to the corresponding LTR-driven vectors. 
The use of cellular promoters as internal promoter (instead of retroviral enhancer-promoters) 
within SIN vectors additionally lowered the risk of genotoxic side effects16.  
 
To develop a SIN vector for p47phox CGD GT we performed two rounds of screening to find a 
potent internal promoter (chapter 1). In the first screen, different myelospecific promoters 
driving GFP expression were tested. GFP as transgene was used as there is no existent pre-
myeloid p47phox -/- cell line which can be propagated to granulocytes. To screen for ex vivo 
myelospecific p47phox transgene expression, human BM cells (e.g. CD34+ from p47phox -/- 
CGD patients) would have been the ideal system. However, as the p47phox -/- CGD11, 12 
disease is rare, it is difficult to get enough of the desired patient cells to perform an ex vivo 
screen. Therefore we decided to use murine primary cells from p47phox -/- mice for a second 
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screen. An earlier study has already shown that the correction of the NADPH oxidase in 
p47phox deficient mice is possible with a LTR-driven vector carrying the human p47phox 
cDNA18.  
At the beginning of our study the obtained SIN γ-retroviral vector titers of the myelospecific 
candidates, which were produced by standard calcium phosphate methodology, were low, as 
observed by others19, 20. By modifying the virus production protocol we could increase the γ-
retroviral titers by two logs. The modifications included (I) optimizing the plasmid 
concentration utilized for virus production (II) shifting from the calcium phosphate method to 
a transfection reagent and (III) concentrating the virus supernatant (chapter 1). Another 
crucial aspect to develop in this thesis was the detection of the p47phox transgene expression. 
p47phox is located within the cytoplasm. In previous p47phox studies, the expression was 
mainly detected by western blot analyses of crude cell extracts21 or indirectly by performing 
functional NADPH oxidase activity assays18. This was not suitable for our purposes, as we 
wanted to analyze the p47phox transgene expression in different hematopoietic cell 
populations to validate for myelospecific expression. We therefore established the ICS with 
an anti-p47phox antibody followed by FACS analysis. This allowed us to measure the p47phox 
transgene expression in the performed second screen and the in vivo experiment in GT 
treated p47phox -/- mice. ICS of the cytoplasmic p47phox transgene product interferes, 
however, with respiratory burst activity. As the induction of phagocytic NADPH-oxidase 
activity requires cellular integrity, it is impossible to combine functional analyses with the 
detection of p47phox protein by immunostaining. To overcome this limitation we developed a 
system in which the expression of the cytoplasmic transgene product is linked to, and can be 
monitored by, the co-expression of a cellular surface marker. A single ORF was created 
encoding the therapeutic transgene linked to the surface marker protein via the FMDV 2A 
peptide. In this 2A-mediated co-expression system the detection of the surface marker 
(∆LNGFR) provides a measure for the expression of the cytoplasmic transgene product 
(chapter 3). Thereby we could show that the NADPH-oxidase activity was restored in 
transgenic mouse granulocytes and human macrophages.  
The establishment of p47phox ICS enabled us to compare p47phox expression in murine stem- 
and progenitor cells with the expression in granulocytes in our screen (chapter 1). By far the 
strongest induction of p47phox expression was observed for the miRNA-223 promoter in our 
second screen. It is not clear at this stage, why only the miRNA-223 promoter out of all 
myelospecific promoter candidates showed clear myelospecific induction upon granulocytic 
differentiation. For all vectors tested, a relatively high p47phox signal in undifferentiated ScaI+ 
cells was observed. As already mentioned in chapter 1, this is likely due to the presence of 
unintegrated circular DNA22 in the stem- and progenitor cells, which is afterwards diluted out 
upon cell division during granulocytic differentiation. This challenge is hard to circumvent as 
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analysis after prolonged culture of undifferentiated ScaI+ cells bears the risk of loosing the 
undifferentiated cells phenotype due to continuous differentiation. If this is true, minor 
myelospecific expression effects can not be detected by this screen. The stem- and 
progenitor cells were pre-cultured in media supplemented with different cytokines. Minor 
changes in the utilized cytokine combination might help to keep the stem- and progenitor 
cells longer in ex vivo culture.  
In our screen in p47phox -/- cells, we observed a strong induction of p47phox expression upon 
myelospecific differentiation by the miRNA-223 promoter, which made this promoter to a 
promising candidate for an in vivo GT in p47phox -/- mice (chapter 2). As expected, the in vivo 
experiment confirmed the myelospecific p47phox expression pattern of the miRNA-223 vector 
in comparison to the constitutively active SFFV control vector. Furthermore, the miRNA-223 
promoter turned out to be highly specific for phagocytes, since there was nearly no or low 
expression in B- and T-lymphocytes, in stem- and progenitor cells, a weak expression in 
splenic monocytes, and a strong expression in granulocytes. These results are in line with a 
performed GT in X-CGD mice in Frankfurt (C. Brendel and M Grez, personal 
communication), in which the miRNA-223 promoter driving gp91phox expression was utilized 
as well. 
 
As gene transfer vehicles we have decided to use γ-retroviral SIN vectors. Another possibility 
would have been the use of a HIV-1-derived lentiviral SIN vectors. Both vector systems show 
efficient transgene expression levels in hematopoietic cells23. In the CGD field γ-retroviral 
(non SIN) MLV vectors have been successfully used for a long time, even in a clinical study1. 
Up to now there is still a lot more reliable experience in safe production and use of γ-
retroviral vectors for clinical GT. Recently it was reported, that even a new PG13-based 
packaging cell line for stable production of clinical-grade SIN γ-retroviral vectors is available 
now 24. We decided therefore to perform our study with γ-retroviral vectors.  
Lentiviral vectors have been successfully utilized for the correction of CGD in tissue culture 
and animal models as well 25, 26. Roesler and coworkers reported on the correction of the 
NADPH oxidase activity in granulocytic cells, which were ex vivo generated from transduced 
human CD34+ cells. In the same study, the correction of the CGD phenotype was also 
reported in vivo after transplantation of transduced human HSC into non-obese diabetic 
(NOD)/SCID mice. A big advantage of the lentiviral vector system is the reduction in time 
necessary for ex vivo manipulation of HSCs. The main reason for this is that lentiviral vectors 
can enter quiescent cells. An extensive pre-culture with cytokines to bring the stem cells into 
cell cycle is not required. However, a very important issue for lentiviral vectors is the 
biosafety considering the pathogenicity of the parental HIV-1 virus in contrast to the MLV 
virus. Compared to the MLV genome, the HIV-1 genome encodes several accessory proteins 
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that enhance efficiency of virus life cycle events and are unfortunately associated with the 
severe pathology of HIV-1. In the past, the design of HIV-1 derived vectors with no ability of 
generating replication-competent retroviruses (RCR) has been achieved by stepwise 
changes in vector and packaging elements, which resulted in third “generations” of HIV-1 
derived vectors. Third generation terms the safest HIV vector generation up to now27-29. 
Recently, a lentiviral SIN vector was successfully used in clinics to treat 3 patients with 
cerebral X-linked adrenoleukodystrophy30. This study was the first published demonstration 
of a GT in HSC with a lentiviral SIN vector.  
GT vectors based on γ-retroviruses and lentiviruses integrate into the genome of transduced 
cells with different integration site preferences31, 32. MLV was found to integrate preferentially 
near the start of transcriptional units, whereas lentiviruses prefer integration into coding 
regions of transcriptional unit, downstream of the transcriptional start site. Whether the 
difference in integration patterns of MLV or lentiviruses influences the risk of insertional 
mutagenesis is a matter of debate. On one hand, Naldini and coworkers have found the MLV 
integration pattern to be significantly more genotoxic than the lentiviral integration pattern in 
in vivo tumor-prone mouse models17. On the other hand, in a canine model retroviral 
integrants of both γ-retrovirus and lentivirus were found within 50kbp around the transcription 
start site33. Considering that activation of proto-oncogene by retroviral integrants can occur 
over long distance (up to 100kb) the different integration pattern between these two vectors 
seem to be too minor to influence genotoxicity8. In the mentioned lentiviral clinical study for 
cerebral X-linked adrenoleukodystrophy30, extensive integration analysis revealed an 
integration site distribution in gene coding regions as expected for lentiviruses. 36 months 
after GT, no signs of clonal dominance or even premalignant disproportional distribution of 
cellular contributions was observed.  
 
The measured p47phox transgene expression in hematopoietic stem- and progenitor cells 
after GT was markedly reduced with the myelospecific miRNA-223 promoter (in comparison 
to the constitutive SFFV control), but not suppressed completely. A complementary strategy 
to target transgene expression to a particular cell type, e.g. granulocytes, could be provided 
by miRNA regulation34. The insertion of a sequence into the untranslated region (3’ UTR), 
which is perfectly complementary to a specific miRNA (which is only present in certain cell 
populations) restricts the transgene expression to cells which do not express the targeted 
miRNA. In cells which express the targeted miRNA, the transgene expression is suppressed 
by degradation of the formed double-stranded RNA. In a recent study several miRNA target 
sequences were identified and tested in a functional reporter assay35. E.g. the miR-126 
target site added to the 3’UTR of the transgene was able to inhibit the transgene expression 
in HSCs and progenitors by endogenous miR-126, but did not prevent the expression in the 
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differentiated progeny. Therefore inclusion of miR-126 target sites in 3’ UTR downstream of 
the p47phox ORF in addition to the miRNA-223 promoter is likely to suppress transgene 
p47phox expression in hematopoietic stem- and progenitor cells.  
 
In our X-CGD GT study1 an increasing discrepancy between gene marking and transgene 
activity was detected in both patients starting day +320. The gp91phox transgene expression 
was silenced but the transactivational activity of the viral enhancer persisted, resulting in 
non-malignant clonal dominance within granulopoiesis6, 7. The mammalian chromosome 
arms contains active chromatin (euchromatin) interspersed with repressive chromatin 
(heterochromatin). Within these regions the histone modifications play a central role in 
regulating gene expression. From yeast organisms it is known that the heterochromatic state 
spreads in cis to flanking chromatin by consecutive methylation of adjacent nucleosomes by 
binding of deacetylating proteins and histone deacetylation36-38. Therefore integration of viral 
construct into silent heterochromatin is expected to result in a spreading of the silent 
chromatin state into the newly introduced viral sequence, as long as spreading from both 
sides is not prevented by insulators39. One option to prevent transgene silencing caused by 
spreading histone modifications in cis from flanking chromatin is the incorporation of insulator 
elements flanking the transgene on both sides. A well characterized insulator is the 5 ’HSE 
chicken beta globin insulator (cHS4). Experimentally it could be shown, that the cHS4 
insulator possesses enhancer blocking activity and reduces position effects40. Silencing can 
also be initiated from the inside of a newly integrated vector after viral integration into 
euchromatin. Neither is the recognition machinery for the „foreign DNA“ known, nor is the 
mechanism of retroviral silencing fully understood. Nevertheless, several silencer elements 
within retroviruses were discovered41. In a retrovirus based construct the CHS4 insulator 
flanking the GFP transgene on both sides failed to block GFP silencing in highly silencing F9 
cells42. To prevent this form of silencing, the newly integrated and insulated expression unit 
has to be kept actively in an open chromatin conformation by including a chromatin opening 
element, e.g. by incorporation of Ubiquitously-acting chromatin opening element (UCOE)43. 
There are indications, that tissue-specific promoters are less prone to silencing compared to 
a constitutive active promoter like SFFV44, 45. However, since there is no precise prediction 
for the miRNA-223 promoter available, this promoter has to be tested in DNA methylation 
assays.  
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Outlook 
We have shown in this study that GT in p47phox -/- mice using our miRNA-223 vector resulted 
in a strictly myelospecific p47phox transgene expression. Furthermore, GT with our vector in 
p47phox -/- mice functionally corrected the CGD phenotype. 
A detailed pre-clinical study is the next step towards a clinical study in human p47phox -/- 
deficient patients. One important issue is that it has to be shown that the newly developed 
GT vector is not genotoxic. This has to be shown in serial transplantation of transduced BM 
stem cells after transduction with high MOI. A malignant transformation in primary or 
secondary transplanted mice would clearly indicate genotoxic potential.  
Furthermore, in vivo efficacy of our vector has to be shown in isolated human p47phox -/- BM 
cells. These cells can be differentiated to neutrophils ex vivo, followed by transgene 
detection and functional analysis of respiratory burst activity26. To ensure that the 
engraftment potential of transduced human HSC is not affected by the vector, human p47phox 
-/- BM cells can be transduced and transplanted in NOD-SCID mice26. As in p47phox -/- mice, 
p47phox expression can be measured by FACS analysis and reconstitution of superoxide 
production can be assayed in gene corrected human neutrophils by a DHR assay. This study 
in addition to the mentioned preclinical experiments should provide more information on 
longterm myelospecific transgene expression and in vivo correction of NADPH oxidase for 
p47phox deficient form of CGD and in the end should lead to a safer GT based treatment 
option for p47phox -/- CGD patients.  
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Abbreviations 
ADA-SCID  adenosine deaminase 
AML acute myeloid leukemia 
BM bone marrow 
BMT bone marrow transplantation 
C. albicans  Candida albicans  
CBP CREB-binding protein 
c/EBPα C/AAT enhancer binding protein 
CGD  chronic granulomatous disease 
cHS4 5’ HSE chicken beta globin insulator 
CIS  common integration site 
CLP common lymphoid progenitor 
CMP  common myeloid progenitor 
CRF  coding reading frame 
DHR dihydrorhodamine  
∆LNGFR  truncated human low-affinity nerve growth factor receptor 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
dsDNA double-stranded DNA 
E.coli Escherichia coli 
EBV Epstein-Barr virus 
EDN  ex vivo differentiated neutrophils 
EF1α elongation factor-1 alpha  
env envelope gene 
ER endoplasmic reticulum 
ErP erythrocyte precursor 
Ets-1 erythroblastosis virus E26 oncogene homologue 1 
Evi1  ecotropic viral integration 1 site 
FACS flow cytometry analysis 
FAD flavin adenin dinucleotide 
FBS foetal bovine serum 
FMDV foot-and-mouth disease virus  
gag group-antigen specific gene 
GALV  gibbon ape leukemia virus envelope  
G-CSF granulocyte colony-stimulating factor 
GDP guanosine diphosphate 
GFP  green fluorescent protein  
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γ-retroviral gammaretroviral 
GT gene therapy 
H2O2  hydrogen peroxide 
HBP1 HMG-box containing protein 1 
HBSS  Hanks’ Buffered Saline Solution  
HEK human embryonic kidney 
HLA human leukocyte antigen 
HMG  high mobility group  
HSC hematopoietic stem cell 
HSCT hematopoietic stem cell transplantation  
ICS intracellular staining 
IFNγ interferon-gamma 
IN  integrase  
IL interleukin 
IRES internal ribosome entry sequence 
IRF-1 interferon regulatory factor 1 
ISRE interferon-stimulated responsive elements 
Lin- BM cells lineage negative bone marrow cells 
Lin- cells cells which do not express any lineage specific antigens 
IVF in vitro fertilization 
LAM-PCR linear amplification-mediated PCR 
LCR  locus control regions  
LSK cells Lin-Sca-1+c-kit+ cells 
LT-HSC longterm self-renewing HSC 
LTR  long terminal repeat 
MDS myelodysplastic syndrome 
MEP  megakaryocyte/erythrocyte progenitors  
MFI mean fluorescence intensity 
mG-CSF murine G-CSF 
miRNA-223 microRNA-223 
MLV mouse leukemia virus 
MOI multiplicity of infection 
MPP multipotent progenitor 
NADPH  reduced nicotinamide adenine dinucleotide phosphate 
NBT nitroblue tetrazolium 
NET  neutrophil extracellular traps  
NIH National Institutes of Health 
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NK natural killer cells 
NOD non-obese diabetic 
OH- hydroxyl radicals  
ORF open reading frame 
PBS primer binding site 
PCR polymerase chain reaction 
PEA3 polyoma virus enhancer activator 3 
PEBP2 phosphatidylethanolamine binding protein 2 
PHOX phagocyte oxidase 
PIC  preintegration complex  
PMA  phorbol 12-myristate 13-acetate 
pol polymerase gene 
polyA polyadenylation site 
PPT polypurine-tract 
PR viral protease 
pro protease gene 
PU.1 Purine Rich Box-1  
q-PCR quantitative PCR 
RCR  replication-competent retroviruses 
RhoGDI Rho GDP-dissociation inhibitor 
RIS  retroviral integration sites 
ROS  reactive oxygen species 
RT  enzyme reverse transcriptase 
SAEs  serious adverse events  
ScaI stem cell associated antigen 
S. aureus  Staphylococcus aureus 
SCID  severe combined immunodeficiency 
SFFV spleen focus-forming virus 
short-term HSC transiently selfrenewing HSC 
SIN  self-inactivating 
ssRNA  single strand RNA 
TF  transcription factor 
UCOE ubiquitously-acting chromatin opening element 
VSV vesicular stomatitis virus 
WPRE  woodchuck hepatitis virus post transcriptional regulatory 
element  
X-CGD X-linked chronic granulomatous disease 
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